[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 144
1. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Hotakainen K, Bjartell A, Sankila A, Järvinen R, Paju A, Rintala E, Haglund C, Stenman UH: Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol; 2006 Jan;28(1):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
  • Tumor-associated trypsin inhibitor (TATI) is a marker of mucinous ovarian carcinoma, but it is also widely expressed in other malignant tumors and normal human tissues.
  • Elevated serum concentrations of TATI are of prognostic value in ovarian, kidney, and bladder cancer.
  • Tumor-associated trypsin is co-expressed with TATI in many malignancies and is thought to be involved in tumor invasion.
  • We used RT-PCR, in situ hybridization and immunohistochemistry to detect trypsinogen- and TATI mRNA and protein in tissue samples from 28 bladder cancer patients and ten benign urothelia.
  • TATI expression was detected in all benign tissues and non-invasive tumors.
  • However, the expression was lower in the muscle-invasive tumors (pT2; n=5), whereas trypsinogen expression was seen in all but one non-invasive tumor.
  • We conclude that trypsinogen is expressed in both malignant and benign bladder epithelium, whereas TATI expression decreases with increasing stage and grade of the tumor.
  • This may suggest that a balanced expression of TATI and trypsinogen is required in normal tissue and that this balance is disrupted during tumor progression.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327984.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 50936-63-5 / Trypsin Inhibitor, Kazal Pancreatic; 9002-08-8 / Trypsinogen
  •  go-up   go-down


3. Hakamada K, Miura T, Kimura A, Nara M, Toyoki Y, Narumi S, Sasak M: Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature. World J Gastroenterol; 2008 Jan 7;14(1):132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature.
  • We herein report an unusual case of anaplastic carcinoma occurring with a recurrent mucinous cystic neoplasm in a 38-year-old female.
  • A 10-cm retroperitoneal cystic mass was pointed out in the first pregnancy and a probable diagnosis of mucinous cystic neoplasm was made in October 2000.
  • During her second pregnancy in 2002, however, she presented hematemesis and underwent urgent distal pancreatectomy, splenectomy and partial resection of the gastric wall where the tumor perforated.
  • A diagnosis of borderline-type mucinous cystic neoplasm with ovarian-like stroma was made.
  • Nine months later, CT visualized a recurrent cystic tumor near the pancreatic stump, which was subsequently resected.
  • Pathology revealed that the tumor was composed of two different components of borderline-type mucinous cystic neoplasm and anaplastic carcinoma.
  • She survived four years after the second surgery without tumor recurrence.
  • Although the origin of anaplastic carcinoma has not been determined yet, it should be remembered that anaplastic carcinoma can occur in association with mucinous cystic neoplasm of more benign histology.
  • [MeSH-major] Carcinoma / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1982 Feb;136(2):157-62 [6278785.001]
  • [Cites] Cell. 1983 Aug;34(1):245-53 [6192933.001]
  • [Cites] Lab Invest. 1987 Oct;57(4):359-69 [3669613.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):494-8 [1702351.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2792-6 [1333354.001]
  • [Cites] Histopathology. 1995 Mar;26(3):284-7 [7541017.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):533-5 [9167613.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Am J Clin Pathol. 1946 Mar;16:219-24 [21027097.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):86-91 [10658914.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):70-80 [8990143.001]
  • (PMID = 18176976.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC2673378
  •  go-up   go-down


Advertisement
4. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN: HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev; 2010;11(1):111-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
  • OBJECTIVES: To evaluate the utility of novel serum tumor markers, HE4 and mesothelin either alone or in combination with CA125 in diagnosis and early detection of ovarian carcinoma in patients with pelvic masses.
  • RESULTS: Of 65 patients with pelvic masses; 41 had histologically diagnosed ovarian cancer, and 24 had benign ovarian diseases.
  • The studied tumor markers were significantly increased in malignant compared to benign cases and healthy subjects, and in benign cases compared to healthy subjects (p<0.001).
  • Based upon Receiver operator characteristic (ROC) curves analysis, HE4 had the highest sensitivity as a single marker in detecting ovarian malignancy (82.9%) and early stage malignancy (76.9%), followed by CA125, then mesothelin.
  • The combination of HE4 and CA125 gave the highest sensitivity in detecting ovarian carcinoma and early stage disease (90.2%, 84.6% respectively).
  • CONCLUSIONS: As a single marker, HE4 had the highest sensitivity for detecting ovarian carcinoma specially early stage disease.
  • Combined CA125 and HE4 was a more accurate predictor of ovarian malignancy than either alone.
  • [MeSH-major] Biomarkers, Tumor / blood. Epididymal Secretory Proteins / metabolism. Membrane Glycoproteins / blood. Ovarian Neoplasms / blood. Pelvic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / pathology. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / pathology. Female. GPI-Linked Proteins. Humans. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Sensitivity and Specificity. beta-Defensins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593939.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  •  go-up   go-down


5. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol; 2006 Sep;19(9):1149-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
  • Overexpression of IGFBP2 and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their role and clinical significance in ovarian cancer has not been investigated in detail.
  • We examined IGFBP2 and IGFBP5 expression levels using two tissue microarrays, one containing six normal surface epithelium, six benign serous cysts, 10 serous borderline tumors, eight low-grade, and 20 high-grade serous carcinomas.
  • The other comprising 441 ovarian cancers of different histologic types linked to a clinicopathologic database.
  • Each tumor was sampled in duplicate with a 1.0-mm punch core needle.
  • IGFBP2 and IGFBP5 were overexpressed in high-grade serous carcinomas compared to normal surface epithelium, benign serous cysts, serous borderline tumors, or low-grade serous carcinoma.
  • They were differentially expressed in different types of ovarian carcinomas, being more often expressed at high levels in high-grade serous carcinoma, malignant mixed mullerian tumors and undifferentiated carcinoma, and more often expressed at low levels or not at all in clear cell and mucinous carcinomas.
  • We concluded that IGFBP2 and IGFBP5 might play a role in the development of high-grade ovarian serous carcinoma, but not in mucinous or clear cell ovarian carcinomas.
  • [MeSH-major] Carcinoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 5 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Neoplasm Staging. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729015.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 5
  •  go-up   go-down


6. Wan T, Liu JH, Zheng LM, Cai MY, Ding T: [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma]. Ai Zheng; 2009 Mar;28(3):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma].
  • BACKGROUND AND OBJECTIVE: Tumor-associated macrophage (TAM) infiltration promotes the progression of various malignancies.
  • This study was to investigate the influence of TAM infiltration on the survival and prognosis of patients with ovarian cancer.
  • METHODS: The expression of CD68, a TAM-specific marker, in 67 specimens of ovarian cancer and 22 specimens of benign ovarian lesion was detected by SP immunohistochemistry to investigate the density of TAM.
  • The correlation of TAM density to the prognosis of ovarian cancer was analyzed.
  • Cox multivariate proportional hazard model was used to analyze prognostic factors of ovarian cancer.
  • RESULTS: Observing under x 400 lens, the mean density of TAM was significantly higher in ovarian cancer than in benign ovarian lesions (57.7 vs. 25.3 per vision field, p<0.01).
  • The 5-year survival rate was significantly higher in low-density TAM group than in high-density TAM group of ovarian cancer patients (73.3% vs. 41.2%, p=0.01).
  • CONCLUSION: TAM infiltration is obvious in advanced ovarian cancer, which indicates poor prognosis.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Age Factors. Aged. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / surgery. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / surgery. Ovarian Cysts / metabolism. Ovarian Cysts / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Proportional Hazards Models. Survival Rate

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619451.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; Ovarian epithelial cancer
  •  go-up   go-down


7. Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW: B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res; 2006 Feb 1;66(3):1570-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
  • Using cDNA database mining strategies and real-time quantitative reverse transcription-PCR, we identified B7-H4 as a novel gene that is overexpressed in ovarian and breast cancer tissues when compared with normal tissues.
  • Immunohistochemistry experiments show plasma membrane staining in serous ovarian and breast cancer, confirming the tissue specificity and cell surface localization.
  • High levels of B7-H4 protein were detected in ovarian cancer tissue lysates when compared with normal tissues.
  • B7-H4 was present at low levels in all sera but showed an elevated level in serum samples from ovarian cancer patients when compared with healthy controls or women with benign gynecologic diseases.
  • The median B7-H4 concentration in endometrioid and serous histotypes was higher than in mucinous histotypes, consistent with results of immunohistochemical staining.
  • We conclude that B7-H4 is a promising new biomarker for ovarian carcinoma.
  • [MeSH-major] Antigens, CD80 / metabolism. Biomarkers, Tumor / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452214.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


8. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of mucinous tumors of the ovary.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • Patients with mucinous carcinoma staged Ib or more were treated postoperatively with 6 cycles of platinum-based chemotherapy.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Hayashi M, Shibazaki M, Sohma R, Inaba N: Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors. Am J Med Sci; 2006 Oct;332(4):181-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
  • BACKGROUND: Normal ovarian tissue is rich in cytokines.
  • Cytokines are important in the physiology of ovarian function.
  • Most of the same cytokines that are found in normal ovarian tissue are also found in association with benign and malignant tumors in contrast to their functions in normal tissues.
  • Thus, we measured macrophage colony-stimulating factor (M-CSF) levels in the liquid contents of benign ovarian tumors--serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma--and investigated whether M-CSF levels were associated with the histologic type of the ovarian tumors.
  • METHODS: We enrolled 65 patients, 52 with benign ovarian tumor and 13 in the early postmenopausal period with symptoms of a menopausal disorder.
  • Among the 52 patients with benign ovarian tumor, 16 had serous cystadenoma, 21 had mucinous cystadenoma, and 15 had mature cystic teratoma.
  • Immediately after surgery, the liquid content was drawn from the ovarian tumor, then centrifuged, and the separated supernatant was stored at -30 degrees C.
  • RESULTS: The level of M-CSF was 12,513 U/mL (median) (range, 0-169,000 U/mL) in serous cystadenoma, 915 U/mL (0-82,500 U/mL) in mucinous cystadenoma, and 149 U/mL (0-6,230 U/mL) in mature cystic teratoma.
  • The M-CSF levels increased significantly from mature cystic teratoma to mucinous cystadenoma to serous cystadenoma.
  • The serum M-CSF levels were 308 to 499 U/mL in patients with benign ovarian tumor.
  • CONCLUSIONS: Elevation of levels of M-CSF varies according to histologic type in benign ovarian tumors.
  • This implies that the antitumor activities of M-CSF for serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma differ by histologic type.
  • [MeSH-major] Extracellular Fluid / metabolism. Macrophage Colony-Stimulating Factor / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031243.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


10. Rosen DG, Yang G, Bast RC Jr, Liu J: Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol; 2006;407:660-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer.
  • Mutations in K-ras or its downstream mediator BRAF have been detected in about two thirds of low-grade serous carcinomas and borderline serous tumors; mutations in K-ras are also often present in benign and invasive mucinous ovarian cancers.
  • Although the oncogenic allele H-ras(V12) is present in only approximately 6% of ovarian cancers, physiologically activated H-ras protein is commonly detected in human ovarian cancer, presumably because of an increase in upstream signals from tyrosine kinase growth factor receptors such as Her-2/neu, despite the lack of a Ras mutation.
  • The methods described here are what we use to culture human ovarian surface epithelial cells, to immortalize those cells, and to transform the immortalized cells with oncogenic H-ras or K-ras.
  • These Ras-transformed human ovarian surface epithelial cells form tumors in nude mice and recapitulate many features of human ovarian cancer, thus providing an excellent model system for studying the initiation and progression of human ovarian cancer.
  • [MeSH-major] Cell Transformation, Neoplastic. Oncogene Protein p21(ras) / pharmacology. Ovarian Neoplasms / physiopathology. Ovary / cytology
  • [MeSH-minor] Animals. Antigens, Viral, Tumor / pharmacology. Cells, Cultured. Epithelial Cells / drug effects. Female. Humans. Immunohistochemistry. Mice. Mice, Nude. Simian virus 40 / immunology. Telomerase / pharmacology. Transfection


11. Zohny SF, Fayed ST: Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol; 2010 Dec;27(4):1246-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.
  • Ovarian cancer remains a highly lethal disease.
  • The aim of the present study was to evaluate the usefulness of measuring serum matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) in comparison with serum cancer antigen 125 (CA 125) for diagnosis of epithelial ovarian cancer (EOC).
  • This study included 51 patients with EOC, 27 patients with benign ovarian lesions and 29 healthy volunteers.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Chemokine CCL11 / blood. Chemokines, CC / blood. Matrix Metalloproteinase 7 / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Prognosis. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):179-87 [10228898.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):374-82 [18584856.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1723-34 [9137096.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66 [17255266.001]
  • [Cites] Open Clin Cancer J. 2008 Feb 06;2:7-12 [18665245.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Immunity. 1999 Feb;10(2):137-42 [10072066.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2647-56 [19351767.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):143-52 [11322833.001]
  • [Cites] Mol Cancer Res. 2006 Nov;4(11):831-41 [17114341.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67 [17828470.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2385-91 [17438097.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24584-93 [11978786.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):273-86 [15781314.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):19-31 [15523695.001]
  • [Cites] J Leukoc Biol. 2005 Jul;78(1):14-26 [15784687.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):879-88 [16152587.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]
  • [Cites] Int Arch Allergy Immunol. 2000 May;122 Suppl 1:54-8 [10867510.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] J Leukoc Biol. 2001 May;69(5):785-93 [11358988.001]
  • [Cites] PLoS One. 2008 Jul 09;3(7):e2633 [18612378.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):713-7 [9192897.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2499-505 [14602136.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):40-8 [11426960.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):92-6 [16278009.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1411-8 [9570561.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):799-809 [9533550.001]
  • [Cites] Biomark Med. 2009 Jun 1;3(3):275-288 [19684876.001]
  • (PMID = 19937162.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CCL11 protein, human; 0 / CCL18 protein, human; 0 / Chemokine CCL11; 0 / Chemokines, CC; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


12. Daponte A, Kostopoulou E, Kollia P, Papamichali R, Vanakara P, Hadjichristodoulou C, Nakou M, Samara S, Koukoulis G, Messinis IE: L1 (CAM) (CD171) in ovarian serous neoplasms. Eur J Gynaecol Oncol; 2008;29(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L1 (CAM) (CD171) in ovarian serous neoplasms.
  • PURPOSE OF THE INVESTIGATION: The evaluation of L1 (CAM) as a tumor progression marker and as a prognostic factor in serous ovarian tumors.
  • METHODS: L1 (CAM) protein expression was assessed by immunohistochemistry and Western blot in serous ovarian tumors [cystadenomas (n = 20), borderline tumors (n = 14) and carcinomas (n = 47)], and was correlated with stage,grade, progression-free survival time (PFS) and overall survival.
  • It increased from benign tumors to early carcinomas and to advanced stage carcinomas progressively and significantly.
  • CONCLUSION: L1 (CAM) expression represents a novel diagnostic marker in serous ovarian neoplasms that shows characteristics of tumor progression.
  • [MeSH-major] Biomarkers, Tumor. Disease-Free Survival. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Neural Cell Adhesion Molecule L1 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386459.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


13. Kamel RM: A massive ovarian mucinous cystadenoma: a case report. Reprod Biol Endocrinol; 2010;8:24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A massive ovarian mucinous cystadenoma: a case report.
  • OBJECTIVES: To report the occurrence of a rare case of a huge benign ovarian tumour (mucinous cystadenoma) in Jazan city, Saudi Arabia.
  • RESULTS: The case was reported as a rare massive ovarian mucinous cystadenoma.
  • [MeSH-major] Cystadenoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis. Tumor Burden

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Adolesc Gynecol. 2005 Dec;18(6):419-22 [16338609.001]
  • [Cites] Arch Gynecol Obstet. 2008 Apr;277(4):379-80 [18236062.001]
  • [Cites] Saudi Med J. 2008 Jan;29(1):126-8 [18176687.001]
  • (PMID = 20222970.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2848663
  •  go-up   go-down


14. Staats PN, Coutts MA, Young RH: Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements. Int J Gynecol Pathol; 2010 May;29(3):228-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements.
  • A 73-year-old woman was found to have a 22 cm unilateral multilocular mucinous cystic tumor of the ovary.
  • Microscopic examination showed a routine appearance of the epithelial component, which ranged from benign to borderline to low-grade carcinoma.
  • The stromal component was unusual because of a striking cellular theca cell component in the stroma, which, in turn, merged with a component of adult granulosa cell tumor.
  • The "parent" neoplasm in this case and 3 other similar cases in the literature appears to be the mucinous neoplasm, in contrast with the other example of mucinous neoplasia associated with sex cord neoplasia, the Sertoli-Leydig cell tumor with heterologous elements, in which the "parent" neoplasm is likely the Sertoli-Leydig cell tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology. Thecoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407320.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Handra-Luca A, Fléjou JF, Rufat P, Corcos O, Belghiti J, Ruszniewski P, Degott C, Bedossa P, Couvelard A: Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology; 2006 Jun;48(7):813-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.
  • AIMS: To examine cytokeratin, epithelial glycoprotein (mucin) and glycoprotein CD10 expression in benign mucinous cystdenomas (MCAs) in comparison with intraductal papillary mucinous adenomas (IPMAs).
  • In MCAs, CD10 was observed both in epithelial cells and in the ovarian-type stromal cells (24/30).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology


16. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH: Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int; 2006 Feb;56(2):62-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
  • To clarify possible roles of adhesion molecules including E-cadherin, beta- and gamma-catenin, CD44s, CD44v6, CD56, and CD99 in ovarian serous neoplasms, an immunohistochemical study was undertaken for 23 benign, 40 borderline, and 95 malignant ovarian serous neoplasms using tissue microarray (TMA).
  • Significantly reduced expression of E-cadherin, and overexpression of CD44s, CD56, and CD99 were more frequently observed in adenocarcinomas than in benign and borderline tumors.
  • Reduced expression of E-cadherin was also correlated with high tumor grade (P=0.03), presence of peritoneal seeding (P=0.03), and low overall survival rate (P=0.02).
  • Overexpression of CD44s was significantly associated with high tumor grade (P=0.04), advanced stage (P=0.03), and low overall survival rate (P=0.02).
  • Nuclear staining for gamma-catenin was correlated with tumor progression (P=0.004) and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.02).
  • These results suggest that although E-cadherin, CD44s, CD56, and nuclear gamma-catenin immuno-expression seem to be useful prognostic markers for serous neoplasm of the ovary, CD44s expression and FIGO stage are independent prognostic factors.
  • [MeSH-major] Cell Adhesion Molecules / analysis. Neoplasms, Cystic, Mucinous, and Serous / chemistry. Neoplasms, Cystic, Mucinous, and Serous / pathology. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. Antigens, CD44 / analysis. Antigens, CD56 / analysis. Cadherins / analysis. Female. Glycoproteins / analysis. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis. Survival Analysis. gamma Catenin / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445817.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD44; 0 / Antigens, CD56; 0 / CD44S antigen; 0 / CD44v6 antigen; 0 / CD99 protein, human; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Glycoproteins; 0 / gamma Catenin
  •  go-up   go-down


17. Kim K, Chung HH, Kim JW, Park NH, Song YS, Kang SB: Clinical impact of under-diagnosis by frozen section examination is minimal in borderline ovarian tumors. Eur J Surg Oncol; 2009 Sep;35(9):969-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of under-diagnosis by frozen section examination is minimal in borderline ovarian tumors.
  • AIMS: The purpose of this study was to examine the clinical impact of under-diagnosis by frozen section examination in borderline ovarian tumors (BOTs).
  • In 61 patients, the frozen section examination under-diagnosed a BOT as a benign tumor.
  • RESULTS: The study group had more mucinous (P=0.03) and/or stage 1A (P=0.02) tumors than the control group.
  • [MeSH-major] Biopsy / methods. Diagnostic Errors. Frozen Sections. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324510.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. J Med Assoc Thai; 2009 Mar;92(3):308-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
  • OBJECTIVE: To investigate the expression of human telomerase reverse transcriptase (hTERT) in epithelial borderline ovarian tumor (BOT) by immunohistochemistry with correlation to clinicopathologic variables.
  • MATERIAL AND METHOD: Paraffin-embedded tissue sections of 62 borderline ovarian tumors (47 mucinous, 14 serous, and 1 clear cell) and 12 epthelial ovarian carcinomas were immunostained with antibodies to hTERT.
  • RESULTS: hTERT expression was detected in 48.4% of BOT and all cases of epithelial ovarian carcinoma.
  • No hTERT immunoreactivity was observed in the benign parts of the same slides of each immunoreactive case. hTERT immunoreactivity was positively correlated with FIGO stage (p = 0.04), but not with other variables.
  • CONCLUSION: hTERT expression was found in half of BOT and all of epithelial ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / enzymology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / pathology. Telomerase / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. RNA, Messenger / genetics. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301721.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


19. Gursan N, Sipal S, Calik M, Gundogdu C: P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med; 2009 Apr;41(1):10-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
  • OBJECTIVE: Approximately 50% of human malignancies present with mutations in p53, which is the most common tumor suppressor gene involved with human malignancies.
  • The purpose of this study was to determine whether simultaneous detection of p53, bcl-2 and Ki-67 using immunohistochemical staining can be used as a diagnostic factor in the assessment of human ovarian epithelial tumors.
  • MATERIALS AND METHODS: The study was performed on formalin-fixed, paraffin-embedded tissue samples from 75 epithelial ovarian tumors, 15 serous cystadenomas, 15 mucinous cystadenomas, 5 borderline serous cystadenomas, 5 borderline mucinous cystadenomas, 15 serous cystadenocarcinomas, 15 mucinous cystadenocarcinomas and 5 endometrioid carcinomas.
  • RESULTS: Anti-p53 reactivity was observed in 14 tumors, all of which were malignant tumors, and no reactivity was observed in borderline or benign tumors.
  • Overexpression of bcl-2 was observed in 12 benign neoplasms (40%), 5 of which were borderline (50%), but was not observed in any of the malignant tumors.
  • There was a statistically significantly higher level of Ki-67 LI positivity in the malignant tumors than in the benign and borderline tumors (p<0.005).
  • CONCLUSION: These data show significant differences in the expression of these markers in ovarian tumors and suggest a possible role for these tumor-associated genes as supplemental tools in diagnostic pathology.
  • Furthermore, our findings support the redesignation of low malignant potential tumors (current nomenclature) to benign ovarian carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25610057.001).
  • [ISSN] 1308-8734
  • [Journal-full-title] The Eurasian journal of medicine
  • [ISO-abbreviation] Eurasian J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC4261648
  • [Keywords] NOTNLM ; Ki-67 / Ovarian cancer / bcl-2 / p53
  •  go-up   go-down


20. Munakata R, Sawair FA, Cheng J, Saku T: Gingival metastasis of ovarian carcinoma: report of a case and review of the literature. Int J Oral Maxillofac Surg; 2009 Oct;38(10):1123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis of ovarian carcinoma: report of a case and review of the literature.
  • Diagnosing gingival metastases is difficult because clinically they can mimic benign oral lesions.
  • The authors report an unusual case of metastatic ovarian carcinoma in the gingiva of a 46-year-old woman 5 years after ovariectomy.
  • The tumor presented as an exophytic growth at the molar region of the mandible.
  • Tumor cells were immunopositive for carcinoembryonic antigen, MUC1 mucin, and lysozyme, while stromal fibroblasts were immunopositive for vimentin and estrogen receptor.
  • The diagnosis of metastatic ovarian mucinous cystadenocarcinoma was made.
  • A review of the English literature revealed this to be the first report of gingival metastasis of an ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / secondary. Gingival Neoplasms / secondary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505797.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / Vimentin
  • [Number-of-references] 27
  •  go-up   go-down


21. Njim L, Moussa A, Saïdani Z, Touil N, Mlik L, Belghith M, Zakhama A: Bilateral ovarian serous borderline tumor with a giant non-invasive peritoneal implant in a four-year-old girl. J Pediatr Adolesc Gynecol; 2010 Feb;23(1):e1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian serous borderline tumor with a giant non-invasive peritoneal implant in a four-year-old girl.
  • Epithelial ovarian tumors are uncommon before 20 years of age and rarely occur before puberty.
  • The vast majority of these tumors are benign, and few cases of malignant and borderline tumors are described.
  • Ultrasonographic examination disclosed bilateral cystic ovarian masses.
  • Laparoscopic exploration revealed bilateral ovarian multicystic masses with retro-uterine peritoneal implant.
  • To our knowledge, there are only four cases of ovarian borderline tumors in premenarchal girls reported in the English literature: three of the mucinous type and only one of the serous type.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19837620.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


22. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • However, there were very few published data regarding the role of maspin in ovarian carcinoma.
  • The aim of the present study was to evaluate maspin expression in ovarian epithelial neoplasms and correlate its expression with some clinicopathologic parameters.
  • MATERIAL AND METHODS: Seventy eight paraffin embedded ovarian specimens from patients with ovarian epithelial neoplasms comprised the material of this study.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • On the other hand, 57.14% of LMP tumors showed weak maspin expression and 63% of malignant ovarian epithelial tumors showed maspin expression with 39.1% over expression.
  • CONCLUSION: Maspin was expressed in a substantial proportion of ovarian tumors with poor prognostic parameters.
  • These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Serine Proteinase Inhibitors / metabolism
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


23. Moolthiya W, Yuenyao P: The risk of malignancy index (RMI) in diagnosis of ovarian malignancy. Asian Pac J Cancer Prev; 2009;10(5):865-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
  • OBJECTIVE: To evaluate the ability of two risk of malignancy indices (RMI) based on serum levels of CA 125, ultrasonographic score, and menopausal status to discriminate between benign and borderline or malignant ovarian tumor.
  • CONCLUSION: The RMI is able to discriminate between benign and borderline or malignant ovarian tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / blood. Cystadenocarcinoma, Serous / diagnosis. Endometrial Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Female. Humans. Middle Aged. Neoplasm Staging. Postmenopause. Radioimmunoassay. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Treatment Outcome. Ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162854.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


24. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis


25. Oku T, Maeda M, Wada Y, Waga E, Ono K, Nagamachi Y, Fujii S, Fujita M, Misu K, Senmaru N, Suzuki Y, Nagashima K, Niitsu Y: Intraductal oncocytic papillary neoplasm having clinical characteristics of mucinous cystic neoplasm and a benign histology. JOP; 2007;8(2):206-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal oncocytic papillary neoplasm having clinical characteristics of mucinous cystic neoplasm and a benign histology.
  • CONTEXT: An intraductal oncocytic papillary neoplasm is a rare pancreatic tumor which was first described by Adsay et al. in 1996.
  • The cellular atypism was mild and the proliferating index was low, compatible with adenoma of an intraductal oncocytic papillary neoplasm.
  • Although no ovarian type stroma was identified, in our case, no communication to main pancreatic duct (located in the pancreatic body) and rapid growth by intracystic hemorrhage were clinical characteristics of a mucinous cystic neoplasm, but not IPMN.
  • CONCLUSION: With only 17 cases reported to date, the clinical and pathological details of an intraductal oncocytic papillary neoplasm are still unclear.
  • To our knowledge, this is the first case report of an intraductal oncocytic papillary neoplasm with the clinical characteristics of a mucinous cystic neoplasm.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356245.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC: Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol; 2007 Aug;106(2):311-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
  • OBJECTIVE: Unlike other histological types of epithelial ovarian carcinoma, ovarian clear cell carcinoma is known to have very poor response to therapy even when discovered in its early stages.
  • Since tumor hypoxia has been shown to be strongly associated with poor prognosis, deregulation of the representative factor of tissue hypoxia; hypoxia-inducible factor 1 alpha (HIF-1alpha) and related protein; Von Hippel-Lindau (VHL) may be associated with poor prognosis of ovarian clear cell carcinoma.
  • METHODS: Immunolocalization of both HIF-1alpha and VHL was performed on 56 cases of paraffin-embedded tissue sections of four different histological types of epithelial ovarian carcinoma and 5 cases of benign ovarian tumors as a control.
  • Quantitative RT-PCR analysis of both HIF1A and VHL was performed on RNA isolated from 61 microdissected frozen tissues of four different histological types of epithelial ovarian carcinoma and 6 cases of normal ovarian epithelial cells.
  • RESULTS: HIF-1alpha expression levels were significantly higher in ovarian clear cell carcinoma than in other histological types (P=0.001).
  • Among endometrioid, serous, and mucinous carcinoma, there were no differences in HIF-1alpha expression (P=0.643).
  • There was a negative correlation between HIF-1alpha and VHL in serous (r=-0.661, P=0.027) and in endometrioid carcinoma (r=-0.657 P=0.039), but no correlation was found between HIF-1alpha and VHL expression levels in ovarian clear cell carcinoma (P=0.60).
  • CONCLUSIONS: The results suggest that the role of hypoxia may change according to the histological type of ovarian carcinoma.
  • High expression of HIF-1alpha and its independence from VHL in ovarian clear cell carcinoma may confer chemoresistance in this histological type.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Med Hypotheses. 2006;66(2):380-3 [16229963.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Biochem J. 2002 Feb 15;362(Pt 1):71-9 [11829741.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1573-81 [12627523.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):297-307 [12927570.001]
  • [Cites] Cancer. 1977 Dec;40(6):3019-29 [589565.001]
  • [Cites] CA Cancer J Clin. 1980 Jan-Feb;30(1):2-15 [6766347.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):199-203 [2807010.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):141-9 [8276286.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Hum Mol Genet. 1994 Dec;3(12):2169-73 [7881415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Kidney Int. 1997 Feb;51(2):560-3 [9027739.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):255-8 [9740700.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6573-86 [9822602.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1973-81 [16123149.001]
  • [Cites] Sci STKE. 2005 Oct 18;2005(306):re12 [16234508.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):343-7 [16051334.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • (PMID = 17532031.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R33 CA103595; United States / NCI NIH HHS / CA / R33 CA103595-04; United States / NCI NIH HHS / CA / CA103595-04; United States / NCI NIH HHS / CA / CA105009-030002; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA105009-030002; United States / PHS HHS / / P50105009; United States / NCI NIH HHS / CA / R01 CA133057; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS28316; NLM/ PMC1995602
  •  go-up   go-down


27. Pickhardt PJ, Hanson ME: Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. Radiology; 2010 Oct;257(1):144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening.
  • Final pathologic findings of surgically excised lesions were cystadenoma or cystadenofibroma (n = 14; 11 serous, three mucinous); nonneoplastic cysts (n = 5; two endometriomas); mature teratoma (n = 3); hydrosalpinx (n = 2); fibroma (n = 1); and benign Brenner tumor (n = 1).
  • No ovarian cancers were prospectively identified, although four cases of ovarian cancer developed subsequent to a negative adnexal finding at CT examination during a 15-44-month interval among the remaining 2751 women.
  • CONCLUSION: Incidental indeterminate adnexal lesions were relatively common at unenhanced CT (4.1%), but subsequent work-up revealed no ovarian cancers.
  • Furthermore, a normal finding at CT was not protective against short-term development of ovarian cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Colonography, Computed Tomographic. Female. Humans. Incidental Findings. Mass Screening. Middle Aged. Ovarian Neoplasms / diagnostic imaging. Ovarian Neoplasms / epidemiology. Postmenopause. Prevalence

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiologe. 2011 Jan;51(1):8 [21153800.001]
  • (PMID = 20663974.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


28. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IeM: Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol; 2007 Apr;26(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of extracellular matrix proteins in ovarian serous tumors.
  • The aims of this study were to perform a comprehensive expression analysis of the genes encoding extracellular matrix proteins and to investigate the expression pattern in one of these proteins, syndecan 1, in normal ovarian epithelium as well as benign and malignant ovarian serous tumors.
  • Gene expression of 16 different extracellular matrix proteins was analyzed in ovarian serous tumors based on serial analysis of gene expression database.
  • As compared with normal ovarian surface epithelium, we found overexpression of syndecan 1, collagen type IV alpha 2, elastin microfibril interfase located protein 1, and laminin 5 in ovarian serous carcinomas.
  • Syndecan 1 was selected for further study as it has not been well characterized in ovarian cancer and the syndecan 1 antibody was available for immunohistochemistry.
  • Using a syndecan 1-specific monoclonal antibody, we demonstrated that syndecan 1 was expressed in 30.4% of high-grade serous carcinomas, 29.7% of low-grade carcinomas and serous borderline tumors, but none of benign serous cystadenomas and ovarian surface epithelium.
  • In summary, ovarian carcinomas exhibit up-regulated expression of several extracellular matrix proteins, and syndecan 1 represents a novel tumor-associated marker in ovarian serous carcinomas.
  • [MeSH-major] Cystadenoma, Serous / metabolism. Extracellular Matrix Proteins / metabolism. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Collagen Type IV / genetics. Collagen Type IV / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Laminin / genetics. Laminin / metabolism. Membrane Glycoproteins / genetics. Membrane Glycoproteins / metabolism. Syndecan-1 / genetics. Syndecan-1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413980.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Extracellular Matrix Proteins; 0 / Laminin; 0 / Membrane Glycoproteins; 0 / Syndecan-1; 0 / elastin microfibril interface located protein
  •  go-up   go-down


29. Zhao Q, Duan W, Wu YM, Qian XH, Deng XH: [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):754-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
  • OBJECTIVE: To find new serum tumor markers for ovarian epithelial cancers by 2-DE DIGE and MALDI-TOF/TOF proteomic methods, in order to improve the diagnostic sensitivity and specificity.
  • METHODS: Serum samples from 103 cases of ovarian epithelial cancers, 60 cases of healthy women, 63 cases of benign ovarian tumors and 63 cases of benign pelvic diseases were collected.
  • Sera of 20 cases of ovarian epithelial cancers (A), 20 cases of ovarian benign tumors (B), 20 cases of pelvic benign diseases (C) and 20 cases of health control (D) were matched by age and pooled, respectively.
  • 2) Western blot and ELISA proved that there were significant differences in Hp and Tf between ovarian epithelial cancers and normal controls (P = 0.000), between ovarian epithelial cancers and ovarian benign tumors (P = 0.000), between ovarian epithelial cancers and benign pelvic disease sera (P = 0.000).
  • 3) CA125 + Hp + Tf combined detection of ovarian cancer had higher sensitivity and specificity than CA125, Hp or Tf detection alone.
  • CONCLUSION: Hp and Tf are differently expressed in the sera of patients with ovarian epitheliual cancers.
  • They can be used as serum biomarkers for ovarian epithelial cancers.
  • CA125 + Hp + Tf combined detection may improve the sensitivity and specificity of diagnosis of ovarian epithelial cancers.
  • [MeSH-major] Cystadenocarcinoma, Serous / blood. Haptoglobins / analysis. Ovarian Neoplasms / blood. Proteins / analysis. Transferrin / analysis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Biomarkers, Tumor / blood. Cystadenocarcinoma, Mucinous / blood. Electrophoresis, Gel, Two-Dimensional. Endometriosis / blood. Female. Humans. Pelvic Inflammatory Disease / blood. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Teratoma / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173805.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Haptoglobins; 0 / NBR1 protein, human; 0 / Proteins; 0 / Transferrin
  •  go-up   go-down


30. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Tumor size ranged from 5.5 to greater than 200 cm.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Mucinous cystadenomas had a varied epithelial lining consisting of lower gastroenteric, gastric foveolar, or müllerian appearance.
  • For mucinous cystadenomas, a cytokeratin (CK) 7+/CK20- phenotype (5/13; 38%) was equally as common as a CK7-/CK20+ phenotype (5/13; 38%), with the remaining cases coexpressing both keratins (CK7+/CK20+: 3/13; 23%).
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • The only adverse outcomes occurred in the 3 patients with ovarian carcinoma and associated peritoneal carcinomatosis.
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • PMP in this setting may harbor microscopic intra-abdominal low-grade mucinous epithelium that is histologically and immunophenotypically similar to that typically seen in appendiceal-related PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary


31. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol; 2007 Feb;19(1):3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Research over the past 50 years has yielded little concrete information on the source of pelvic serous cancer in women, creating a knowledge gap that has adversely influenced our ability to identify, remove or prevent the earliest stages of the most lethal form of ovarian cancer.
  • Tubal intraepithelial carcinoma is present in many women with presumed ovarian or peritoneal serous cancer.
  • A candidate precursor to tubal intraepithelial carcinoma, entitled the 'p53 signature', suggests that molecular events associated with serous cancer (p53 mutations) may be detected in benign mucosa.
  • The emerging data offer compelling evidence for a model of 'fimbrial-ovarian' serous neoplasia, and call attention to the distal fallopian tube as an important source for this disease, the study of which could clarify pathways to cancer in both organs and generate novel strategies for cancer prevention.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Fallopian Tube Neoplasms / pathology. Genes, BRCA1. Peritoneal Neoplasms / etiology
  • [MeSH-minor] Carcinoma in Situ / etiology. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic. Female. Humans. Ovarian Neoplasms / etiology. Ovarian Neoplasms / pathology. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218844.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 43
  •  go-up   go-down


32. Bar JK, Słomska I, Rabczyńki J, Noga L, Gryboś M: Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int J Gynecol Cancer; 2009 Nov;19(8):1322-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
  • The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression.
  • METHODS: p53 protein expression was evaluated on tissues from malignant and benign ovarian tumors.
  • RESULTS: The correlation between p53 protein overexpression and p53-Ser392 phosphorylation was found in ovarian carcinomas (P = 0.001, r = +0.27).
  • In the total group of ovarian carcinomas, significant differences were observed in p53 protein overexpression between well (G1) and poor (G3) tumor grades (P = 0.005) and between serous and endometrioid types of tumor (P = 0.04), whereas p53-Ser20 phosphorylation was associated with advanced International Federation of Gynecology and Obstetrics stage (P = 0.004) and high tumor grade (P = 0.02).
  • In p53-positive ovarian carcinomas, p53-Ser392 phosphorylation was associated with advanced tumor stage (P = 0.02) and high tumor grade (P = 0.049).
  • p53-Ser20 phosphorylation was associated with low tumor grade of p53-positive ovarian carcinomas (P = 0.02) and with high tumor grade of p53-negative ovarian carcinomas (P = 0.02).
  • CONCLUSIONS: These results revealed that p53 phosphorylation at Ser20 and Ser392 is an early event in ovarian tumor development.
  • The authors suggest that the expression of p53 protein phosphorylated at Ser20 and Ser392 in ovarian carcinomas determines their individual clinical features depending on p53 protein status and may be useful biological biomarkers characterizing their behavior.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Serine / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. Young Adult


33. Hackethal A, Brueggmann D, Turovets M, Bassaly B, Stein A, Gerber EL, Muenstedt K: Removal of enormous bilateral mucinous cystadenomas of the ovaries with abdominal plastic reconstruction. Arch Gynecol Obstet; 2009 Jan;279(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Removal of enormous bilateral mucinous cystadenomas of the ovaries with abdominal plastic reconstruction.
  • INTRODUCTION: Bilateral mucinous cystadenoma of the ovary are extremely rare.
  • These tumors are benign and might lead to abdominal distension, if no secondary symptoms occur and patient delay the consultation of physicians.
  • Tumor excision was initiated and final histology revealed bilateral mucinous cystadenoma of the ovaries.
  • Total tumor excision is necessary because the heterogeneous composition requires careful examination by pathologists to rule out borderline tumors and non-invasive carcinomas.
  • After tumor excision an abdominal wall reconstruction might be necessary because of the laxity and redundancy of the skin.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386030.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Tsuchiya T, Nakahama K, Asakawa Y, Maemura T, Tanaka M, Takeda S, Morita M, Morita I: The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor. Gynecol Endocrinol; 2009 Feb;25(2):104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
  • The aim of this study was to characterise the roles of angiogenic and anti-angiogenic factors on ovarian cancer.
  • METHODS: The expression levels of vascular endothelial growth factor (VEGF, angiogenic factor) and pigment epithelial growth factor (PEDF, anti-angiogenic factor) were measured by real-time polymerase chain reaction and Western blotting in ovarian tumors.
  • Microvessel density (MVD) was evaluated by the total microvessel length in high-power field of tumor tissue preparations.
  • RESULTS: MVD correlated with tumor malignancy.
  • The VEGF expression levels in some malignant tumors (VEGF-L) were as low as that in benign tumors.
  • The PEDF expression levels in VEGF-L malignant tumors were significantly lower than those in benign tumors.
  • On the other hand, the PEDF expression levels in VEGF-H malignant tumor tissues were not significantly different from those in benign tumors.
  • CONCLUSION: The reduction in PEDF expression levels may be, in part, responsible for tumor malignancy in VEGF-L ovarian tumors.
  • Furthermore, PEDF may be a useful marker of malignancy in VEGF-L ovarian tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / physiopathology. Eye Proteins / genetics. Nerve Growth Factors / genetics. Ovarian Neoplasms / pathology. Ovarian Neoplasms / physiopathology. Serpins / genetics. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood supply. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / physiopathology. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Endometrioid / blood supply. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / physiopathology. Female. Gene Expression Regulation, Neoplastic. Humans. Microcirculation / physiology. Neoplasms / blood supply. Neoplasms / pathology. Neoplasms / physiopathology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253105.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Eye Proteins; 0 / Nerve Growth Factors; 0 / Serpins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / pigment epithelium-derived factor
  •  go-up   go-down


35. Hu CJ, Zhang F, Chen YJ, Sun XM, Zheng JF: [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
  • OBJECTIVE: To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer.
  • METHODS: The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer.
  • RESULTS: The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01).
  • The expression of hK6 in higher-grade ovarian cancer tissues (68.4% ) was higher than that in low-grade ones (14.3%, P < 0.05).
  • CONCLUSION: The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms.
  • The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis. hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Kallikreins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950700.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


36. Chiesa AG, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A: Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol; 2010 Mar;29(2):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
  • At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed.
  • Optimal sampling and adequate sampling were defined as at least 1 section per centimeter of maximum tumor dimension and at least 1 section per 2 cm of maximum tumor dimension, respectively.
  • Tumor size ranged from 8 to 39 cm (mean 20 cm).
  • The sampling of the ovarian tumor was optimal in 28 cases and adequate in 5 cases.
  • The tumor was incompletely removed and recurred in the pelvis 1 year later.
  • Ten months later, the tumor re-recurred in the pelvis and could only be drained because of the patient's advanced age and her poor medical status.
  • The second patient with recurrent tumor had undergone a cystectomy and full staging for a borderline OInMT.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Histocytochemistry. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Terminology as Topic. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Nov;29(6):552-3; author reply 553-4 [20881857.001]
  • (PMID = 20173495.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Lee JH, Zhang X, Shin BK, Lee ES, Kim I: Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study. Pathology; 2009;41(3):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study.
  • AIM: We used a new differential display method, the annealing control primer (ACP) system, to analyse the differentially expressed genes in mucinous ovarian tumours.
  • METHODS AND RESULTS: The ACP-based reverse transcriptase-polymerase chain reaction revealed that 21 genes were upregulated in the mucinous ovarian adenoma and 14 genes were upregulated in the mucinous ovarian carcinoma.
  • Among them, we selected one upregulated gene, the Mac-2 binding protein (Mac-2 BP), and verified the expression of the Mac-2 BP and its ligand, galectin-3, in a variety of epithelial ovarian tumours by immunohistochemistry.
  • Positive expression of the Mac-2 BP was significantly higher in the mucinous ovarian tumours compared to the other epithelial tumours.
  • Mac-2 BP expression was significantly increased in the borderline and malignant tumours compared to the benign tumours.
  • Galectin-3 expression was more frequent in clear cell carcinomas, serous tumours and mucinous tumours than in endometrioid and transitional tumours.
  • However, there were no differences in galectin-3 expression in comparisons among benign, borderline and malignant mucinous and serous tumours.
  • CONCLUSION: These data indicate that the Mac-2 BP may play a role in the development and progression of mucinous ovarian tumours.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cystadenocarcinoma, Mucinous / metabolism. DNA Primers. Galectin 3 / biosynthesis. Gene Expression Profiling / methods. Membrane Glycoproteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Female. Gene Expression. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction / methods. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291534.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / Galectin 3; 0 / Membrane Glycoproteins; 0 / TAA90K protein, human
  •  go-up   go-down


38. Zhang LL, Shao SL, Wu Y: [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chin J Cancer; 2010 Jan;29(1):25-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].
  • BACKGROUND AND OBJECTIVE: Epithelial ovarian cancer involves a number of factors.
  • Recent studies have shown that osteopontin (OPN) is related to the occurrence and development of a variety of tumors, but few studies are on ovarian cancer.
  • B7-H4 is a newly identified tumor marker in ovarian cancer.
  • This study explored the expression of OPN and B7-H4 and their clinical significance in epithelial ovarian tumors.
  • METHODS: The expression of OPN and B7-H4 in 15 cases of normal ovarian tissue, 20 of benign ovarian tumor tissue, 20 of borderline ovarian tumor tissue, and 40 of ovarian cancer tissue were detected by immunohistochemistry, and the relationship of OPN and B7-H4 expression to clinical and pathologic features of ovarian cancer was analyzed.
  • RESULTS: The expression of OPN and B7-H4 were significantly higher in ovarian cancer than in borderline and benign tumors (P<0.05).
  • The positive rates of OPN and B7-H4 were significantly higher in poorly differentiated ovarian cancer than in medium and highly differentiated ovarian cancer (P<0.05), and the levels of expression were significantly lower in tissue at stages I and III of ovarian cancer than in stages III and IV (P<0.05).
  • The positive rate of B7-H4 were significantly higher in ovarian serous carcinoma than in the mucinous carcinoma (P<0.05), but did not relate to age and lymph node metastasis.
  • CONCLUSION: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. V-Set Domain-Containing T-Cell Activation Inhibitor 1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038306.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 106441-73-0 / Osteopontin; Ovarian epithelial cancer
  •  go-up   go-down


39. Gojnic M, Dugalic V, Vidaković S, Papic M, Jeremic K, Pervulov M, Milicevic S: Breast cancer and borderline ovarian carcinoma in young patients--case report. Eur J Gynaecol Oncol; 2005;26(5):579-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer and borderline ovarian carcinoma in young patients--case report.
  • Borderline ovarian tumors comprise 10% to 15% of all epithelial tumors of the ovary.
  • Regardless of the tumor type (serous, mucinous, clear cell, Brenner, mixed) they can be benign, borderline or malignant.
  • [MeSH-major] Breast Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Phyllodes Tumor / diagnosis


40. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
  • Ovarian cancer is the most lethal gynecologic malignancy.
  • Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and pathogenesis of epithelial ovarian cancer are poorly understood.
  • This has led to the proposal that ovarian cancer develops de novo.
  • Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features.
  • One group of tumors, designated type I, is composed of low-grade serous, low-grade endometrioid, clear cell, mucinous and transitional (Brenner) carcinomas.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • Recent studies have also provided cogent evidence that what have been traditionally thought to be primary ovarian tumors actually originate in other pelvic organs and involve the ovary secondarily.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.
  • As it is generally accepted that endometriosis develops from endometrial tissue by retrograde menstruation, it is reasonable to assume that the endometrium is the source of these ovarian neoplasms.
  • Finally, preliminary data suggest that mucinous and transitional (Brenner) tumors arise from transitional-type epithelial nests at the tubal-mesothelial junction by a process of metaplasia.


41. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • Expressions of P-LAP and GLUT-4 in ovarian cancer cells were detected by Western blotting.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • P-LAP was expressed in 23 of 29 in serous, 15 of 17 endometrioid, 13 of 14 mucinous, and all clear-cell adenocarcinomas.
  • GLUT4 was expressed in 13 of 29 serous, 13 of 17 endometrioid, 13 of 14 mucinous, and 18 of 20 clear-cell adenocarcinomas.
  • CONCLUSIONS: P-LAP and GLUT4 are available not only for the evaluation of ovarian epithelial malignancy, but also as targets for molecular therapy.
  • Further study to investigate the roles of P-LAP and GLUT4 in ovarian carcinoma is needed.
  • [MeSH-major] Cystinyl Aminopeptidase / biosynthesis. Monosaccharide Transport Proteins / biosynthesis. Muscle Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


42. Cai Z, Li YF, Liu FY, Feng YL, Hou JH, Zhao MQ: [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]. Ai Zheng; 2007 Mar;26(3):312-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
  • However, their correlations to epithelial ovarian cancer have seldom been reported.
  • This study was to investigate the roles of uPA and PAI-1 in the invasion and metastasis of epithelial ovarian cancer, to clarify their localization and relationship with prognosis.
  • METHODS: Immunohistochemistry was applied to examine the protein expression of uPA and PAI-1 in 80 specimens of epithelial ovarian cancer and 20 specimens of benign ovarian tumor.
  • RESULTS: The positive rates of uPA and PAI-1 were significantly higher in epithelial ovarian cancer than in benign ovarian tumor (77.5% vs. 30.0%, P<0.001; 55.0% vs. 20.0%, P=0.005).
  • uPA expression was correlated positively to PAI-1 expression in epithelial ovarian cancer (P=0.001).
  • Higher positive rate of uPA was associated with greater metastatic tumor in the peritoneal cavity (P=0.038), but not associated with age, FIGO stage, histological type, pathologic grade, serum CA125 level, ovarian tumor size, and the size of residual tumor (P>0.05).
  • CONCLUSION: Both uPA and PAI-1 are up-regulated in epithelial ovarian cancer, and might be used as markers to predict the prognosis of epithelial ovarian cancer patients.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Plasminogen Activator Inhibitor 1 / metabolism. Urokinase-Type Plasminogen Activator / metabolism
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Neoplasm Staging. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355798.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Plasminogen Activator Inhibitor 1; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


43. Ferreira CR, Carvalho JP, Soares FA, Siqueira SA, Carvalho FM: Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
  • Pseudomyxoma peritonei (PMP) is a clinical condition initially thought to be related to ovarian mucinous tumors; however, immunohistochemistry and molecular biology techniques have convincingly made the link to appendiceal mucinous neoplasms, resulting in changes in histologic and clinical approaches.
  • The objective of this study was to compare the immunohistochemical profile of ovarian tumors associated with PMP and intestinal mucinous ovarian neoplasms without PMP.
  • The study was retrospective and included 28 intestinal ovarian mucinous tumors selected from the files of the Division of Surgical Pathology of the University of Sao Paulo Medical School, from 1996 to 2005.
  • Comparisons of borderline histology with that of benign/malignant tumors also revealed differences in MUC2 and CK20.
  • Our results confirm that there is a distinct profile of intestinal ovarian tumors associated with pseudomyxoma, particularly with respect to the expression of the gel-forming mucin MUC2.
  • The profile of borderline tumors, even in cases without PMP, was distinct from that of other primary mucinous tumors of the intestinal type, suggesting that borderline histology may represent a secondary tumor or a less aggressive variant of PMP.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Intestinal Neoplasms / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Pseudomyxoma Peritonei / pathology


44. Takaori K, Hruban RH, Maitra A, Tanigawa N: Current topics on precursors to pancreatic cancer. Adv Med Sci; 2006;51:23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and pancreatic intraepithelial neoplasias (PanINs) all harbor varying degrees of dysplasia and stepwise accumulation of genetic alterations, suggesting progression of these lesions from benign toward malignant neoplasms.
  • MCNs have a characteristic ovarian-type stroma.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Disease Progression. Humans. Models, Biological. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357272.001).
  • [ISSN] 1896-1126
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 81
  •  go-up   go-down


45. Pylväs M, Puistola U, Kauppila S, Soini Y, Karihtala P: Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer; 2010 Jun;46(9):1661-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis.
  • However, there is only some information about their role in ovarian carcinogenesis or in ovarian carcinomas in vivo.
  • We studied immunohistochemical nuclear and/or cytoplasmic expression of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and nitrotyrosine, as well as major antioxidative enzymes peroxiredoxins (PRDX) I-VI and thioredoxin (TXN) in ovarian tumours.
  • The material consisted of 20 benign (10 serous, 10 mucinous) and 51 borderline (33 serous, 18 mucinous) epithelial ovarian tumours.
  • The markers of oxidative stress, 8-OHdG and nitrotyrosine, were seen already in benign tumours (in 20% and 45% of the tumours, respectively) and their expression patterns were similar in benign and borderline tumours.
  • The levels of PRDX II, III, IV, V and VI were significantly higher in borderline than in benign tumours (p<0.02 for all).
  • Specifically for PRDX II (for both nuclear and cytoplasmic expression, p<0.00005) and PRDX VI (for cytoplasmic expression, p=0.0003 and for nuclear expression, p=0.0005) the difference between benign and borderline tumours was remarkable.
  • In general, serous benign and borderline tumours expressed higher antioxidant enzyme levels than mucinous ones.
  • Nuclear TXN was expressed more strongly in benign than in borderline tumours (p=0.003).
  • Oxidative stress occurs already in benign ovarian tumours and the levels are comparable to borderline tumours.
  • However, some of the antioxidant enzymes, especially PRDX II and VI, are more profoundly induced in borderline ovarian tumours, reflecting their possible role as cancer preventers.
  • This difference could also offer a potential tool for differential diagnosis between benign and borderline epithelial ovarian tumours.
  • [MeSH-major] Antioxidants / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / enzymology. Oxidative Stress / physiology
  • [MeSH-minor] Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Female. Humans. Immunohistochemistry. Peroxiredoxins / metabolism. Reactive Oxygen Species / metabolism. Thioredoxins / metabolism. Tyrosine / analogs & derivatives. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206498.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Reactive Oxygen Species; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 52500-60-4 / Thioredoxins; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.11.1.15 / Peroxiredoxins; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


46. Sun PM, Wei LH, Luo MY, Liu G, Wang JL, Mustea A, Könsgen D, Lichtenegger W, Sehouli J: The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. Eur J Obstet Gynecol Reprod Biol; 2007 Feb;130(2):249-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer.
  • OBJECTIVE: The aim of this study was to evaluate the clinicopathological significance of telomerase activity and expression of hTERT gene in human ovarian cancer.
  • The potential value of them as indicators for chemotherapy in ovarian cancer cells was also studied.
  • MATERIALS AND METHODS: A total of 73 samples and ovarian cancer cell lines HO-8910 and COC1 were studied.
  • Alteration of the telomerase activity and hTERT mRNA were also analyzed in the ovarian cancer cells treated with different concentration and different time of cisplatin.
  • RESULTS: Telomerase activity are highly increased in malignancy (0.795+/-0.168(A450-655 nm)) than borderline (0.389+/-0.174(A450-655 nm)), benign tumors (0.236+/-0.102(A450-655 nm)) and normal ovary (0.213+/-0.070(A450-655 nm)) (p < 0.05).
  • Both of they may be useful in the predicting of chemotherapeutic effect in ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Ovarian Neoplasms / genetics. Ovary / metabolism. RNA, Messenger / analysis. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Gene Expression. Humans. Middle Aged. Predictive Value of Tests. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519988.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


47. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • Those that are mucinous, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), constitute the most important category, not only because they are the most common, but more importantly because they have well-established malignant potential, representing an adenomacarcinoma sequence.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • For this reason, pancreatic cysts with mucinous differentiation ought to be evaluated carefully, preferably by experts familiar with subtle evidences of malignancy in these tumors.
  • The presence of ovarian-type stroma has now almost become a requirement for the diagnosis of MCN, and when defined as such, MCN is seen almost exclusively in women of perimenopausal age group as thick-walled multilocular cystic mass in the tail of the pancreas in contrast with IPMN which afflicts an elder population, both genders in almost equal numbers, and occur predominantly in the head of the organ.
  • While mucinous lesions have well-established pre-malignant properties, most of the entities that fall into the nonmucinous true cyst category such as serous tumors, lymphoepithelial cysts, congenital cysts, and squamoid cyst of ducts have virtually no malignant potential.
  • In contrast, the rare cystic tumors that occur as a result of degenerative/necrotic changes in otherwise solid neoplasia such as the rare cystic ductal adenocarcinomas, cystic endocrine neoplasia, and most importantly, solid-pseudopapillary tumor (SPT) in which cystic change is so common that it used to be incorporated into its name ("solid-cystic," "papillary-cystic") are malignant neoplasia, albeit variable degrees of aggressiveness.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-major] Adenoma / pathology. Carcinoma in Situ / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Cystadenoma / pathology. Cystadenoma, Serous / pathology. Dilatation, Pathologic. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


48. Tannuri AC, Tannuri U, Gibelli NE, Romão RL: Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg; 2009 Nov;44(11):2083-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After neoadjuvant chemotherapy, tumor resectability was evaluated by another CT scan.
  • RESULTS: Fifty-three children with hepatic tumors underwent surgical treatment, 47 patients underwent liver resections, and in 6 cases, liver transplantation was performed because the tumor was considered unresectable.
  • Ten children presented with other malignant tumors-3 undifferentiated sarcomas, 2 hepatocellular carcinomas, 2 fibrolamellar hepatocellular carcinomas, a rhabdomyosarcoma, an immature ovarian teratoma, and a single neuroblastoma.
  • Six children had benign tumors-4 mesenchymal hamartoma, 1 focal nodular hyperplasia, and a mucinous cystadenoma.
  • [MeSH-minor] Age Factors. Blood Loss, Surgical. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Follow-Up Studies. Hepatectomy / methods. Hepatoblastoma / mortality. Hepatoblastoma / surgery. Humans. Infant. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


49. Esheba GE, Pate LL, Longacre TA: Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol; 2008 Apr;32(4):600-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary is the surface epithelial neoplasm most often confused with primitive germ cell tumors, particularly yolk sac tumor (YST) and dysgerminoma.
  • To investigate whether GPC3 is useful in distinguishing YST from ovarian CCC, we studied the expression of GPC3 in a large series of ovarian neoplasms and compared it to the expression profiles of CK7 and alpha-fetoprotein.
  • Tissue microarrays containing over 400 benign and malignant ovarian neoplasms, including 34 CCCs were stained with monoclonal GPC3 (clone 1G12, Biomosaics, Burlington, VT).
  • These arrays contained a wide assortment of ovarian surface epithelial neoplasms and sex cord stromal neoplasms, as well as germ cell tumors.
  • All but one YST (97%), including those associated with mixed germ cell tumor were positive for GPC3, whereas all teratomas and embryonal carcinomas were negative.
  • Most CCCs (83%) were completely negative for GPC3, as were 99% serous, 94% endometrioid, and 100% mucinous tumors.
  • GPC3 seems to be a promising diagnostic marker for differentiating YST from ovarian CCC (P < 0.0001).
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Endodermal Sinus Tumor / chemistry. Glypicans / analysis. Ovarian Neoplasms / chemistry

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277882.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / alpha-Fetoproteins; 0 / oncofetal antigens
  •  go-up   go-down


50. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • In nine of the 12 cases, distinct nuclear immunostaining for HNF-1beta was detected in the endometriotic epithelium, as well as in the clear cell tumor.
  • Furthermore, 16 of 40 (40%) endometriotic cysts without a neoplasm also expressed HNF-1beta, and the expression was almost exclusively observed in the epithelium showing inflammatory atypia.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • Early differentiation into the clear cell lineage takes place in ovarian endometriosis, not only in atypical endometriosis, but also in endometriosis with degenerative and regenerative changes, and this is probably responsible for the frequent occurrence of clear cell carcinoma in ovarian endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


51. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol; 2006 Jan;100(1):44-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H4 overexpression in ovarian tumors.
  • OBJECTIVES: Despite great advances in therapeutic management, the mortality rate for ovarian cancer has remained relatively stable over the past 50 years.
  • This study was designed to evaluate the expression of B7-H4 protein, recently identified as a potential molecular marker of breast and ovarian cancer by quantitative PCR analysis, in benign tumors, tumors of low malignant potential and malignant tumors of the ovary.
  • METHODS: Archival formalin-fixed tissue blocks from serous, mucinous, endometrioid and clear cell ovarian tumors were evaluated by immunohistochemistry for the distribution of B7-H4 expression, and staining intensity was measured by automated image analysis.
  • RESULTS: B7-H4 cytoplasmic and membranous expression was detected in all primary serous (n = 32), endometrioid (n = 12), and clear cell carcinomas (n = 15), and in all metastatic serous (n = 23) and endometrioid (n = 7) ovarian carcinomas.
  • By contrast, focal B7-H4 expression was detected in only 1/11 mucinous carcinomas.
  • CONCLUSIONS: The consistent overexpression of B7-H4 in serous, endometrioid and clear cell ovarian carcinomas and the relative absence of expression in most normal somatic tissues indicates that B7-H4 should be further investigated as a potential diagnostic marker or therapeutic target for ovarian cancer.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256178.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


52. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • Glypican-3 is currently regarded as a tumor marker and potential target for immunotherapy.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • Among the benign lesions examined, glypican-3 expression was identified exclusively in the endometrial epithelium in the gestational period.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; P<0.0001).
  • All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3.
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


53. El Ayed M, Bonnel D, Longuespée R, Castelier C, Franck J, Vergara D, Desmons A, Tasiemski A, Kenani A, Vinatier D, Day R, Fournier I, Salzet M: MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit; 2010 Aug;16(8):BR233-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers.
  • We propose an analytical tool to track ovarian carcinoma biomarkers, that is, the MALDI mass spectrometry imaging.
  • MATERIAL/METHODS: Ovarian carcinomas and benign ovaries were directly analyzed by MALDI-TOF-MS.
  • RESULTS: A list of specific biomarkers from the ovarian carcinoma regions was obtained and classified as proteins associated with cell proliferation, involved in immune response modulation, signaling to the cytoskeleton, and tumor progression.
  • These specific biomarkers were then validated by immunocytochemistry using Tag-mass technology, cell biology, Western blot, and by PCR (using SKOV-3 ovarian epithelial cancer cells).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous. Amino Acid Sequence. Female. Gene Expression Regulation, Neoplastic. Humans. Molecular Sequence Data. Molecular Weight. Nanotechnology. Neoplasm Proteins / chemistry. Neoplasm Proteins / metabolism. Neoplasm Staging. Principal Component Analysis. Reproducibility of Results

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20671603.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


54. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Signet ring cells were present in sufficient quantity for a diagnosis of Krukenberg tumor in four tumors.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Jordan SJ, Green AC, Whiteman DC, Webb PM, Australian Ovarian Cancer Study Group: Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol; 2007 Nov;107(2):223-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
  • OBJECTIVE: Some molecular and histological evidence suggests that mucinous epithelial ovarian cancers develop via a sequence from benign tumor through borderline tumor to invasive cancer.
  • Such a sequence would predict some shared risk factors between the different tumor types.
  • To investigate this, we examined risk factors for benign, borderline and invasive mucinous ovarian tumors.
  • Women with benign (n=133), borderline (n=147) and invasive (n=43) mucinous tumors of the ovary and women from the general population (n=1487) completed comprehensive health and lifestyle questionnaires.
  • RESULTS: Although parity was inversely related to risk of benign, borderline and invasive tumors, increasing numbers of births did not further decrease risk of any of the tumor types.
  • However, 20 or more pack-years of smoking was associated with a more than twofold increase in risk of all three tumor types (OR=2.7, 95% CI 1.6-4.4 for benign tumors; OR=2.7, 95% CI 1.7-4.4 for borderline tumors; and OR=2.1, 95% CI 0.9-5.0 for invasive cancers) compared to never smoking.
  • CONCLUSIONS: Overall, the risk factors for mucinous cancers appear to differ from other subtypes of ovarian cancer.
  • Furthermore, patterns of risk factors across benign, borderline and invasive mucinous ovarian tumors are generally consistent with an adenoma-to-carcinoma sequence as the developmental pathway for this subtype of ovarian cancer.
  • Our findings also suggest the potential preventability of borderline and invasive mucinous ovarian cancer by smoking cessation and by surgical excision of identifiable precursor lesions.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / etiology. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / etiology. Precancerous Conditions / epidemiology
  • [MeSH-minor] Adult. Aged. Australia. Case-Control Studies. Cell Transformation, Neoplastic / pathology. Female. Health Status. Humans. Life Style. Middle Aged. Neoplasm Invasiveness. Odds Ratio. Reproductive History. Risk Assessment. Risk Factors. Smoking / adverse effects. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662378.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


56. Poli Neto OB, Candido Dos Reis FJ, Zambelli Ramalho LN, Nogueira AA, de Andrade JM: p63 expression in epithelial ovarian tumors. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):152-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 expression in epithelial ovarian tumors.
  • Ovarian cancer is a highly lethal disease and its underlying biology is poorly understood.
  • The p63 is a homologue gene of the tumor suppressor p53. p63 appears to be important for the development and differentiation of reproductive epithelium and interacts with p53 in human tumorigenesis.
  • This study presents the immunoexpression of the p63 in benign and malignant epithelial ovarian tumors.
  • We evaluated the p63 immunoexpression in 91 ovarian benign cystadenomas (29 mucinous and 62 serous) and in 29 ovarian malignant tumors (3 mucinous borderline, 3 serous borderline, 17 serous carcinomas, 2 endometrioid, 2 undifferentiated, 1 mucinous, and 1 clear-cell carcinoma) using a monoclonal antibody clone 4A4 (1:200), which recognizes all p63 variants.
  • We observed 85.7% of positivity in benign tumors, 50% in borderline tumors, and 8.7% in invasive ovarian cancer (P < .0001).
  • The benign serous cystadenomas were positive in 91.9% of cases and benign mucinous cystadenomas in 72.4% (P= .02).
  • These data suggests an important role of p63 in the control of ovarian epithelium behavior.
  • The p63 may be involved in the development of benign and malignant epithelial ovarian tumors.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Cystadenoma / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Phosphoproteins / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / analysis. Biopsy, Needle. Cohort Studies. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Sensitivity and Specificity. Tissue Culture Techniques. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445626.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


57. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res; 2005 Mar 15;65(6):2162-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
  • Among the genes most commonly identified in gene expression profiles of epithelial ovarian carcinomas (EOC) is the gene for human epididymis protein 4 (HE4).
  • To ascertain its clinical utility, we did a comprehensive assessment of HE4 protein expression in benign and malignant ovarian and nonovarian tissues by immunohistochemistry.
  • Its expression in tumors was restricted to certain histologic subtype: 93% of serous and 100% of endometrioid EOCs expressed HE4, whereas only 50% and 0% of clear cell carcinomas and mucinous tumors, respectively, were positive.
  • Using reverse transcription-PCR, we identified ovarian cancer cell lines that endogenously overexpress HE4.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Epididymal Secretory Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Epithelium / metabolism. Female. Humans. Mullerian Ducts / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. beta-Defensins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781627.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / RNA, Messenger; 0 / beta-Defensins
  •  go-up   go-down


58. Wootipoom V, Dechsukhum C, Hanprasertpong J, Lim A: Accuracy of intraoperative frozen section in diagnosis of ovarian tumors. J Med Assoc Thai; 2006 May;89(5):577-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of intraoperative frozen section in diagnosis of ovarian tumors.
  • OBJECTIVE: To determine the accuracy of intraoperative frozen section diagnosis of ovarian tumors according to malignancy status.
  • MATERIAL AND METHOD: From May, 1999 to October, 2004 at Songklanagarind Hospital, a total of 229 ovarian specimens were transferred from the operating room to the Department of Pathology for intraoperative frozen section.
  • RESULTS: Intraoperative frozen section diagnosis of all 229 ovarian specimens revealed 54.1% benign tumors, 8.3% borderline tumors, 30.6% malignant tumors, and 7% deferred diagnoses.
  • The final paraffin section diagnoses revealed 52.4% benign tumors, 9.2% borderline tumors, and 38.4% malignant tumors.
  • Mean tumor diameter of the agreement cases were 12.58 +/- 5.39 cm, disagreement cases were 17.64 +/- 6.83 cm, and deferred cases were 19.33 +/- 6.50 cm.
  • The mean diameter of mucinous tumors was significantly different comparing between disagreement cases to agreement cases and deferred cases to agreement cases.
  • Sensitivity was highest in the benign group at 98.2% and lowest in the borderline group at 57.1%.
  • The sensitivity and specificity for benign, borderline, and malignant tumors were 98.2%, 57.1%, 86.1%, and 87.0%, 96.4%, 98.5%, respectively.
  • The Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for benign, borderline, malignant tumors were 89.5%, 63.2%, 97.1% and 97.8%, 95.4%, 92.3%, respectively.
  • CONCLUSION: Intraoperative frozen section diagnosis appears to be an accurate technique for the histopathologic diagnosis of ovarian tumors.
  • However, limitations in use of frozen section must be recognized such as large specimens, especially mucinous subtype.
  • Regular re-evaluation or consultation concerning disagreements between frozen section diagnosis and final permanent paraffin diagnosis should be conducted by both surgeons and pathologists as part of quality assurance to determine the most appropriate intraoperative management for patients with ovarian tumors.
  • [MeSH-major] Monitoring, Intraoperative. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756039.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


59. Jordan SJ, Green AC, Whiteman DC, Webb PM: Risk factors for benign serous and mucinous epithelial ovarian tumors. Obstet Gynecol; 2007 Mar;109(3):647-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign serous and mucinous epithelial ovarian tumors.
  • OBJECTIVE: To investigate the risk factors for benign serous and mucinous epithelial ovarian tumors.
  • METHODS: Cases were women newly diagnosed with benign serous ovarian tumors (n=230) or benign mucinous tumors (n=133) between 2002 and 2005.
  • RESULTS: Current smoking was associated with a three-fold increase in risk of benign mucinous tumors (OR 3.25, 95% CI 1.97-5.34), and there was a trend of increasing risk with increasing amount smoked (P<.001).
  • Both recent obesity (OR 1.93, 95% CI 1.30-2.88) and obesity at age 20 (OR 4.38, 95% CI 1.88-10.20) were associated with increased risk of benign serous ovarian tumors, and having had a hysterectomy was also related to increased risk of serous (OR 2.75, 95% CI 1.90-3.96), but not mucinous tumors.
  • Ever having had a term pregnancy was inversely associated with both tumor types (combined OR 0.65, 95% CI 0.43-0.97), although greater numbers of pregnancies did not decrease risk further.
  • CONCLUSION: Our results suggest some differences in risk factors between benign serous and mucinous epithelial ovarian tumors and that risk factors for benign serous tumors differ from those well established for ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / epidemiology. Cystadenocarcinoma, Serous / epidemiology. Ovarian Neoplasms / epidemiology. Smoking / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329516.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


60. Wang XY, Dai JR, Zhu Z, Zhao YF, Zhou CW: [CT features of ovarian Brenner tumor and a report of 9 cases]. Zhonghua Zhong Liu Za Zhi; 2010 May;32(5):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CT features of ovarian Brenner tumor and a report of 9 cases].
  • OBJECTIVE: In order to improve the preoperative diagnostic accuracy, the computed tomographic (CT) features of ovarian Brenner tumor were described and analyzed.
  • METHODS: CT image and clinical data of nine patients with pathologically confirmed Brenner tumor were collected and analyzed retrospectively.
  • There were 8 benign lesions and 1 borderline lesion.
  • Among the nine cases, 5 were benign tumors with uniform structure, 3 were benign tumors accompanied with other pathological components, and 1 was borderline tumor.
  • On the CT images, the 5 uniform benign lesions showed to be solid tumor of low density (lower than that of muscle) or with small cyst inside, two of the 5 lesions had calcification, and other 2 lesions showed slightly heterogeneous enhancement after enhanced scanning.
  • The 3 benign Brenner tumors accompanied with other pathological structures were solid-cystic or cystic, with a clear demarcation of solid and cystic components.
  • The one borderline tumor was a heterogeneous solid one and its density was higher than that of muscle, with a large proportion of low density and large calcification, and moderately enhanced after enhancing.
  • CONCLUSION: Ovarian Brenner tumors are usually unilateral and often accompanied with other type of tumor components.
  • When a tumor is of uniform component, the CT imaging often shows a homogeneous solid tumor with homogeneous or heterogeneous density.
  • When a tumor is accompanied with other tumor components, it may be solid-cystic or cystic and has partial calcification.
  • After enhancing, a benign Brenner tumor is slightly enhanced, while the borderline one is moderately/highly enhanced.
  • [MeSH-major] Brenner Tumor / radiography. Ovarian Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / diagnosis. Cystadenoma, Mucinous / radiography. Cystadenoma, Serous / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged. Ovary / radiography. Sex Cord-Gonadal Stromal Tumors / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723434.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


61. Malkan AD, Braich PS, Panait L, Dudrick SJ: Mucinous cystadenoma of the ovary presenting as unilateral lower extremity edema. Conn Med; 2009 Oct;73(9):517-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the ovary presenting as unilateral lower extremity edema.
  • INTRODUCTION: Mucinous cystadenomas of the ovary are known for their potential to grow to massive proportions and are often incidentally diagnosed.
  • They are typically benign tumors accounting for 15% of ovarian neoplasms and up to 80% of all mucinous tumors.
  • CASE REPORT: We report a 50-year-old, morbidly obese female admitted with left lower extremity edema who was incidentally found to have a massive, benign, mucinous cystadenoma of the ovary.
  • The tumor was managed by laparotomy, cystectomy, and right salpingo-oophorectomy.
  • Pathology revealed a benign cyst.
  • CONCLUSION: The clinically silent course of these large, benign tumors can have unique presentations.
  • [MeSH-major] Cystadenoma, Mucinous / diagnosis. Edema / etiology. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Conn Med. 2013 Aug;77(7):448. Singh-Braich, Puneet [corrected to Braich, Puneet Singh]
  • (PMID = 19860270.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Kolwijck E, Massuger LF, Thomas CM, Span PN, Krasovec M, Kos J, Sweep FC: Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. J Cancer Res Clin Oncol; 2010 May;136(5):771-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors.
  • INTRODUCTION: In cancer, an extracellular and membrane bound localization of cathepsins contribute to the invasion of tumor cells at the basement membrane.
  • METHODS: This is the first study that explored levels of cathepsins B (CatB), L (CatL) and their inhibitor cystatin C (CysC) in the cystic fluid (CF) of ovarian tumors (n = 110).
  • Remarkable differences in CatB and CatL and CysC CF levels were found between different histopathological tumor subtypes.
  • Levels of CatB and CysC were significantly higher in CF of malignant serous tumors compared to those found in benign serous tumors (p = 0.010 and p = 0.001 respectively), whereas levels of CatL were significantly higher in CF of malignant mucinous tumors compared to those found in benign mucinous tumors (p = 0.035).
  • CONCLUSION: Further studies are warranted to investigate cathepsins as possible prognostic biomarkers for the aggressiveness of ovarian cancer.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsin L / metabolism. Cyst Fluid / metabolism. Cystatin C / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1980 Mar 6;284(5751):67-8 [6243750.001]
  • [Cites] Histopathology. 2001 Feb;38(2):87-95 [11207821.001]
  • [Cites] Cancer Metastasis Rev. 1990 Dec;9(4):333-52 [2097084.001]
  • [Cites] Cancer Lett. 1992 Jan 31;61(3):243-53 [1739949.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1992 Feb;30(2):69-74 [1316176.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):537-44 [8420674.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):357-61 [7705668.001]
  • [Cites] Mol Cell Biochem. 1995 Mar 9;144(1):35-43 [7791743.001]
  • [Cites] Neoplasma. 1995;42(1):21-4 [7617069.001]
  • [Cites] Clin Chim Acta. 1995 Jun 15;237(1-2):67-78 [7664480.001]
  • [Cites] Biol Chem Hoppe Seyler. 1995 Jul;376(7):401-5 [7576236.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Oncology. 1997 Jan-Feb;54(1):79-83 [8978598.001]
  • [Cites] Pancreas. 1997 Jan;14(1):22-7 [8981503.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1997 Apr;35(4):301-4 [9166974.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1511-6 [9626470.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):613-8 [9816210.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1815-22 [9815568.001]
  • [Cites] Clin Chim Acta. 1999 Apr;282(1-2):211-8 [10340450.001]
  • [Cites] Int J Gynaecol Obstet. 1999 Jun;65(3):243-9 [10428343.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):904-13 [16508639.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1230-40 [16315320.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79 [17018256.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):508-15 [17113137.001]
  • [Cites] Cancer Lett. 2007 Apr 18;248(2):192-7 [16945481.001]
  • [Cites] J Histochem Cytochem. 2007 Aug;55(8):867-75 [17478446.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] PLoS Med. 2008 Dec 2;5(12):e232 [19053170.001]
  • [Cites] Neoplasma. 2001;48(1):66-71 [11327540.001]
  • [Cites] Surg Today. 2001;31(5):385-9 [11381499.001]
  • [Cites] Biol Chem. 2001 May;382(5):805-10 [11517934.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1802-15 [12365030.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):160-6 [14751152.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):881-6 [14984956.001]
  • [Cites] Clin Chim Acta. 2004 Jun;344(1-2):155-61 [15149884.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2573-7 [15330217.001]
  • [Cites] Int J Gynecol Pathol. 2004 Oct;23(4):316-20 [15381900.001]
  • [Cites] Clin Chim Acta. 2000 Jan 20;291(1):89-95 [10612720.001]
  • [Cites] Clin Chem. 2000 Feb;46(2):193-7 [10657375.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):98-111 [10708852.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):84-9 [10763147.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):90-3 [10763148.001]
  • [Cites] Exp Gerontol. 1986;21(4-5):379-406 [3545873.001]
  • (PMID = 19915865.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cystatin C; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / Cathepsin L
  • [Other-IDs] NLM/ PMC2841751
  •  go-up   go-down


63. D'Angelo E, Dadmanesh F, Pecorelli S, Prat J: Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type. Int J Gynecol Pathol; 2010 Nov;29(6):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type.
  • We studied a 58-year-old woman in whom a keratinizing squamous cell carcinoma of the ovary had arisen from a mucinous cystic tumor of endocervical (müllerian) type.
  • The tumor was interpreted initially as a transitional cell carcinoma of the ovary with marked squamous differentiation, but there was no evidence of either transitional cell carcinoma or malignant Brenner tumor.
  • The mucinous columnar epithelial component was largely benign and only focally proliferative or borderline.
  • As found typically in endocervical (müllerian) mucinous tumors, numerous polymorphonuclear leukocytes were seen in the stroma and the neoplastic mucinous epithelium.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cystadenoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2011 Jul;30(4):396-7 [21623198.001]
  • (PMID = 20881861.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Histologic types are serous, mucinous, endometrioid, clear cell, or Brenner.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


65. Khunamornpong S, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Young RH: Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia. Am J Surg Pathol; 2007 Dec;31(12):1788-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia.
  • The potential for adenocarcinoma metastatic to the ovary to mimic primary mucinous neoplasms is a well-known issue to surgical pathologists, most of the recent literature emphasizing pancreatic and various other origins for the ovarian metastases.
  • Thirteen presented with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The hepatic tumors were radiologically detected before the ovarian lesion in 2 cases.
  • Hepatic and ovarian masses were simultaneously detected by preoperative radiologic studies or at exploratory laparotomy in 10 cases.
  • There were a total of 26 metastatic ovarian lesions which included 22 clinically recognized ovarian masses (range 3 to 20 cm, mean 11.8 cm).
  • The epithelium ranged from tall, columnar, and mucinous in appearance to cuboidal or flattened and nonspecific.
  • The tumors most closely mimicked primary mucinous neoplasms although a resemblance to other mullerian neoplasms was also seen.
  • Foci often mimicked mucinous borderline tumors of typical type or with intraepithelial carcinoma and benign-appearing mucinous epithelium was seen in 62% of tumors.
  • Intrahepatic cholangiocarcinoma should be included in the list of origins of possible ovarian metastatic tumors that mimic primary ovarian mucinous neoplasia, particularly in parts of the world where cholangiocarcinoma of the liver is relatively common.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / secondary. Ovarian Neoplasms / secondary


66. Gryshkova V, Goncharuk I, Gurtovyy V, Khozhayenko Y, Nespryadko S, Vorobjova L, Usenko V, Gout I, Filonenko V, Kiyamova R: The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer. Exp Oncol; 2009 Mar;31(1):37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer.
  • The identification of markers that are specifically expressed by different histological types of epithelial ovarian cancer (EOC) may lead to the development of novel and more specific diagnostic and therapeutic strategies.
  • Sodium-dependent phosphate transporter NaPi2b (or MX35 ovarian cancer antigen) is a novel perspective marker of EOC.
  • AIM: To examine NaPi2b/MX35 expression in different histological types of epithelial ovarian tumors.
  • METHODS: Here, we describe the analysis of NaPi2b expression in serous (n = 17), endometrioid (n = 8), and mucinous ovarian tumors (n = 3) by Western-blotting (WB), immunohistochemistry and RT-PCR.
  • RESULTS: The results of immunohistochemical and WB analysis showed that benign and well-differentiated malignant papillary serous tumors as well as well-differentiated malignant endometriod tumors overexpress NaPi2b protein.
  • However, no overexpression of NaPi2b was detected in benign and malignant mucinous tumors as well as in poorly differentiated endometriod tumors.
  • CONCLUSION: We have shown the differential expression profile of NaPi2b phosphate transporter at protein level in various histological types of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Endometrioid / genetics. Neoplasms, Cystic, Mucinous, and Serous / genetics. Ovarian Neoplasms / genetics. Phosphate Transport Proteins / genetics


67. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors.
  • Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type.
  • The most common and best understood are serous borderline tumors and mucinous borderline tumors of intestinal type, which are the subject of this review.
  • Some of the most challenging issues for serous tumors include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal tumor implants, especially invasive implants; and, the prognostic significance of micropapillary tumors.
  • The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
  • All of these issues are discussed in this presentation, as are the important gross and microscopic features of serous and mucinous borderline tumors and pertinent information on their treatment and prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


68. Okamoto S, Ito K, Sasano H, Moriya T, Niikura H, Terada Y, Sato S, Okamura K, Yaegashi N: Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med; 2005 May;206(1):31-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells.
  • The differential diagnosis between reactive mesothelial cells and ovarian carcinoma cells is often difficult in cytologic specimens.
  • Furthermore, previous studies examined only serous type but not other histological types of ovarian carcinoma cases.
  • Various types of ovarian carcinoma (serous, n = 22; mucinous, n = 10; endometrioid, n = 7; clear cell, n = 10) and benign mesothelial tissues (n = 15) were studied by immunohistochemistry.
  • In the tissue specimens, Ber-EP4, a monoclonal antibody of epithelial antigen, and a polyclonal antibody against calretinin, which is expressed in mesothelium, are used in differentiating reactive mesothelial cells from ovarian carcinoma.
  • In conclusion, the combined immunostaining of cytologic specimens for Ber-EP4 and the anti-calretinin antibody is helpful for the differential diagnosis between mesothelial cells and not only serous type, but also mucinous, endometrioid and clear cell types of ovarian cancer cells.
  • [MeSH-major] Antibodies. Biomarkers, Tumor / immunology. Epithelium / immunology. Ovarian Neoplasms / diagnosis. S100 Calcium Binding Protein G / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802873.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / human epithelial antigen-125
  •  go-up   go-down


69. Guo AT, Wei LX, Song X: [Histologic classification and prognostic implication of pseudomyxoma peritonei]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):474-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases were histologically classified into 3 subcategories: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and PMCA with intermediate or discordant features (PMCA-I/D).
  • The age and sex of patients, frequency of operation and presence of ovarian involvement did not correlate with duration of survival.
  • On the other hand, the presence of appendiceal tumor, parenchymal invasion of abdominal viscera, cellularity, architecture, nuclear atypia and mitotic activity of the peritoneal lesion significantly correlated with survival.
  • CONCLUSIONS: In general, the 10-year survival rate of PMP was low, despite the relatively benign-looking or low-grade pathologic appearance.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Adult. Aged. Appendectomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845762.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Takahashi N, Yamamoto E, Ino K, Miyoshi E, Nagasaka T, Kajiyama H, Shibata K, Nawa A, Kikkawa F: High expression of N-acetylglucosaminyltransferase V in mucinous tumors of the ovary. Oncol Rep; 2009 Nov;22(5):1027-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of N-acetylglucosaminyltransferase V in mucinous tumors of the ovary.
  • The present study aimed to investigate GnT-V expression and its prognostic significance in epithelial ovarian cancer.
  • GnT-V expression was studied by immunohistochemistry in 83 surgically resected ovarian cancers, and the staining intensity was evaluated.
  • In the histological type, mucinous adenocarcinoma showed significantly strong immunostaining compared to the non-mucinous type (P<0.001).
  • In 36 mucinous tumors, the GnT-V immunostaining score was significantly higher in cancer than in benign and borderline tumors (P<0.001).
  • NOM-1, a human ovarian mucinous adenocarcinoma cell line, expressed strong GnT-V protein and swainsonine treatment suppressed beta1-6GlcNAc branching and reduced migration ability significantly (P<0.001).
  • These results suggested that GnT-V might be involved in the malignant potential of mucinous ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Mucinous / enzymology. Cystadenocarcinoma, Serous / enzymology. Endometrial Neoplasms / enzymology. N-Acetylglucosaminyltransferases / metabolism. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Adhesion. Cell Movement. Cell Proliferation. Female. Humans. Immunoenzyme Techniques. Middle Aged. Phytohemagglutinins / metabolism. Prognosis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787216.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Phytohemagglutinins; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.155 / alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase
  •  go-up   go-down


71. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M: Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int; 2009 May;59(5):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.
  • Tumor-associated macrophages (TAM) are known to possess the immunosuppressive M2 macrophage phenotype.
  • They contribute to tumor growth, invasion, and metastasis by producing various mediators.
  • Macrophages, especially M2 polarized macrophages, preferentially express CD163 and CD204, but few studies have investigated macrophage phenotypes in human ovarian tumors.
  • The purpose of the present study was therefore to present results on macrophage differentiation in human ovarian serous and mucinous epithelial tumors.
  • The method focused on immunostaining of paraffin-embedded tumor samples.
  • Almost all macrophages infiltrating tumor tissues expressed CD163 and CD204, indicating the phenotypic shift toward M2 macrophage.
  • The numbers of CD68-positive macrophages as well as of CD163- and CD204-positive macrophages in borderline and malignant tumors were significantly higher than in benign tumors.
  • CSF-1 expression in malignant tumor cells was significantly higher than that in benign tumor cells and correlated with histological malignancy.
  • These results suggest that CSF-1 derived from tumor tissues induces macrophages to shift toward the M2 phenotype, which is considered to promote tumor growth.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / immunology. Cystadenocarcinoma, Serous / immunology. Macrophage Colony-Stimulating Factor / biosynthesis. Macrophages / immunology. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD / immunology. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / immunology. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Differentiation / immunology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / immunology. Phenotype. Receptors, Cell Surface / immunology. Receptors, Cell Surface / metabolism. Scavenger Receptors, Class A / immunology. Scavenger Receptors, Class A / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432671.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / MSR1 protein, human; 0 / Receptors, Cell Surface; 0 / Scavenger Receptors, Class A; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


72. Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, Kumja P, Wanaphirak C, Sugahara K, Hardingham T, Kongtawelert P: Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem; 2006 Oct;140(4):517-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer.
  • OBJECTIVE: To determine the value of serum chondroitin sulfate epitope WF6 and hyaluronan (HA) levels as a biomarker for early detection of ovarian epithelial cancer and other gynecological disorders.
  • METHOD: Serum WF6 CS epitope and HA were measured in 91 patients with ovarian epithelial cancer, 39 patients with non-cancer gynecological disorders and 30 healthy women.
  • RESULTS: The serum concentration of CS (WF6) epitope was highly increased in epithelial types of ovarian cancer and at all stages of development (p < 0.005).
  • Serum HA in ovarian cancer patients was significantly higher than normal controls (p < 0.05).
  • CONCLUSION: These results reflect changes in ECM metabolism in progressive ovarian cancer, which cause an increase in serum CS epitopes and HA.
  • Measurement of serum HA provided complementary information, which may be useful as a discriminator between benign ovarian disorders and malignant ovarian diseases.
  • [MeSH-major] Chondroitin Sulfates / blood. Hyaluronic Acid / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / immunology. Adenocarcinoma, Papillary / pathology. Adult. Aged. Antibodies, Monoclonal. Biomarkers, Tumor / blood. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / pathology. Cells, Cultured. Cross-Sectional Studies. Epitopes. Female. Humans. Hybridomas. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936295.001).
  • [ISSN] 0021-924X
  • [Journal-full-title] Journal of biochemistry
  • [ISO-abbreviation] J. Biochem.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 9004-61-9 / Hyaluronic Acid; 9007-28-7 / Chondroitin Sulfates
  •  go-up   go-down


73. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Kabukcuoglu S, Oner U, Ozalp SS, Bildirici K, Yalcin OT, Colak E: The role of actin bundling protein fascin in the progression of ovarian neoplasms. Eur J Gynaecol Oncol; 2006;27(2):171-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of actin bundling protein fascin in the progression of ovarian neoplasms.
  • PURPOSE OF INVESTIGATION: The aim of the study was to investigate the role of fascin in tumor progression and to investigate the role of fascin on endothelial cell migration and angiogenesis in ovarian neoplasms.
  • METHODS: In the study, 94 malign epithelial ovarian neoplasms, 13 borderline epithelial ovarian neoplasms, 25 serous and mucinous cystadenomas and four normal ovarian tissues were examined by means of immunohistochemistry, using monoclonal antihuman fascin antibody, clone IM20.
  • RESULTS: Total stromal fascin score in cases of borderline and malign epithelial ovarian tumors was significantly higher compared to normal ovaries and benign epithelial ovarian tumors (.000, p < 0.001).
  • There was no significant difference in terms of mean microvessel count and homogeneous or heterogeneous fascin expression of microvessels between the benign and malign groups (respectively p = .228 and p = .143).
  • CONCLUSIONS: This study suggests that up-regulation of fascin in tumoral tissue may promote invasion of ovarian carcinoma by cell-matrix adhesion.
  • [MeSH-major] Actins / metabolism. Carrier Proteins / metabolism. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Microfilament Proteins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620064.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


75. Wang CJ, Chao A, Lai CH, Huang SY, Lee CL, Soong YK: Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses. J Laparoendosc Adv Surg Tech A; 2009 Oct;19(5):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses.
  • OBJECTIVE: The aim of this study was to present our experience with laparoscopically assisted vaginal ovarian cystectomy (LAVOC) in selected patients with various large ovarian masses.
  • MATERIALS AND METHODS: Among the medical records of 324 patients with ovarian masses, 10 consecutive women of reproductive age with prior sexual activity and with large ovarian masses (10-27 cm) were evaluated.
  • A combined laparoscopic and vaginal ovarian cystectomy was done through the posterior cul-de-sac.
  • RESULTS: All operations proceeded smoothly; the ovarian pathologies included 1 mucinous cystadenoma, 1 serous cystadenoma, 1 mucinous cystadenoma coexisting with mature cystic teratoma, and 7 mature cystic teratomas.
  • The median (range) tumor size was 15.5 cm (range, 10-27), operative duration was 62 minutes (range, 31-110), the estimated blood loss 50 mL (range, 10-150), and the hospital stay was 2 days (range, 1-4).
  • [MeSH-major] Cystadenoma / surgery. Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Female. Humans. Laparoscopy. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715487.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Presneau N, Shen Z, Provencher D, Mes-Masson AM, Tonin PN: Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol; 2005 Jun;26(6):1621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors.
  • Previous studies have implicated the chromosomal region at 17q25 as harboring tumor suppressor genes based on the frequent loss of heterozygosity (LOH) observed in epithelial ovarian cancers (EOC).
  • In contrast to three other EOC cell lines (TOV81D, TOV112D and TOV21G) and primary cultures derived from normal ovarian surface epithelial cells (NOSE), sequence analysis of the cDNA revealed a deletion of G at position 1484 of the transcribed sequence which is located within the 3'UTR of H3F3B.
  • OV90 was derived from ascites fluid of an undifferentiated adenocarcinoma of ovarian origin.
  • The variant allele was identified in 1 of 65 (2%) healthy women with no prior history of cancer and in 5 participants with ovarian tumors comprising of 4 of 79 (5%) malignant EOC, none of 10 low malignancy potential tumors, and 1 of 8 (13%) benign tumors.
  • All carriers of the variant alleles were heterozygous and tumor samples did not exhibit preferential LOH of the normal allele.
  • The variant allele was identified in EOC samples of clear cell (1 of 20), mucinous (1 of 8), mixed cell (1 of 3) and undifferentiated (1 of 2) histopathological subtypes but none of 34 serous or 12 endometrioid subtype tumors.
  • One of 3 mucinous benign tumors also harbored the variant allele.
  • The functional significance of the variant is unknown, however its presence in rare subtypes of ovarian epithelial tumors warrants further investigation.
  • [MeSH-major] 3' Untranslated Regions / genetics. Histones / genetics. Loss of Heterozygosity. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Chromosome Mapping. Chromosomes, Human, Pair 17. Female. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870878.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Histones
  •  go-up   go-down


77. Okuma E, Ohishi Y, Oda Y, Aishima S, Kurihara S, Nishimura I, Yasunaga M, Kobayashi H, Wake N, Tsuneyoshi M: Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type. Oncol Rep; 2010 Dec;24(6):1569-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type.
  • Ovarian mucinous neoplasms of gastro-intestinal type (GI-type) are known to be a heterogeneous tumor composed of benign, borderline and non-invasive and invasive malignant lesions.
  • The presence of infiltrative invasion is also known to be an important prognostic factor of this neoplasm.
  • Laminin γ 2 chain, known to stimulate tumor cell invasion and migration, has not been sufficiently investigated in ovarian mucinous neoplasms.
  • The purpose of this study was thus to clarify the role of laminin γ 2 in ovarian mucinous neoplasms of GI-type.
  • We selected each morphological phase of tumor development from 61 cases of mucinous neoplasms of the GI-type: 55 adenoma lesions, 60 borderline lesions, 20 microinvasive lesions, 17 intraepithelial carcinoma lesions, 38 expansile invasive carcinoma lesions, 19 infiltrative invasive carcinoma lesions and 5 mural nodules lesions; and evaluated the localization of laminin γ 2 in the lesions using immunohistochemical method.
  • The infiltrative invasion of GI-type ovarian mucinous neoplasms may be promoted by cytoplasmic and/or stromal expression of laminin γ 2 chain.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastrointestinal Neoplasms / pathology. Laminin / metabolism. Neoplasm Staging / methods. Ovarian Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cohort Studies. Cytoplasm / metabolism. Disease Progression. Female. Humans. Models, Biological. Neoplasm Invasiveness. Prognosis. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042753.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


78. Hefler-Frischmuth K, Hefler LA, Heinze G, Paseka V, Grimm C, Tempfer CB: Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol; 2009 Nov;147(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum C-reactive protein in the differential diagnosis of ovarian masses.
  • OBJECTIVE: A number of serum tumor markers have been investigated to aid clinicians in the differential diagnosis of ovarian masses.
  • Serum C-reactive protein (CRP) is a widely used biomarker of inflammation and has been previously shown to be a promising biomarker in patients with ovarian cancer.
  • STUDY DESIGN: In a retrospective single-center study, we evaluated serum CRP in 576 patients with benign and in 242 patients with malignant (ovarian tumors of low malignant potential [LMP]: n=44, epithelial ovarian cancer [EOC]: n=198) ovarian masses.
  • RESULTS: Median (25th, 75th percentiles) serum CRP in patients with benign ovarian tumors, with ovarian tumors of LMP, and with EOC were 0.5 (0.5, 0.6)mg/dL, 0.5 (0.5, 0.9)mg/dL, and 1.36 (0.5, 4.9)mg/dL, respectively (p<0.001).
  • In the subgroup of patients with EOC, serum CRP significantly correlated with FIGO stage (p<0.001), residual tumor mass (p<0.001), and patients' age (p=0.04), but not with tumor grade (p=0.2) and histologic type (p=0.4).
  • In univariable and multivariable models including serum CRP, serum CA 125, and patients' age, serum CRP independently predicted the presence of malignant ovarian masses (p<0.0001; Odds Ratio [OR] 5.3, 95% Confidence Interval [CI] 3.8-7.4).
  • Serum CRP had a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying malignant ovarian masses of 49.8%, 84.1%, 57.1%, and 79.8%, respectively.
  • CONCLUSION: Serum CRP is associated with the presence of malignant ovarian tumors independent of serum CA 125 and patients' age and can therefore be used as additional diagnostic marker in the differential diagnosis of ovarian masses.
  • [MeSH-major] Biomarkers, Tumor / blood. C-Reactive Protein / metabolism. Ovarian Diseases / blood. Ovarian Diseases / diagnosis. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Cystadenoma, Mucinous / blood. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Serous / blood. Cystadenoma, Serous / diagnosis. Diagnosis, Differential. Endometriosis / blood. Endometriosis / diagnosis. Female. Humans. Middle Aged. Ovarian Cysts / blood. Ovarian Cysts / diagnosis. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619929.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


79. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer; 2005 Dec 20;117(6):1049-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
  • Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as the separate gain of chromosome bands 8q21 and 8q24 has been reported in independent studies.
  • Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry.
  • These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype.
  • TPD52 subcellular localization was predominantly cytoplasmic, although nuclear localization was also frequently observed in mucinous and clear cell carcinomas.
  • TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number.
  • [MeSH-major] Gene Amplification / genetics. Gene Expression. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-125 Antigen / blood. Chromosomes, Human, Pair 8. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


80. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ: Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol; 2005 Jan;96(1):48-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.
  • OBJECTIVE: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models.
  • METHODS: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCID mice within 2 h of surgical removal.
  • Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types.
  • RESULTS: Tumor tissue engraftment rate was > 95%.
  • CONCLUSIONS: Subrenal capsule xenografts of primary human ovarian tumors in SCID mice can retain major histopathological and immunohistochemical characteristics of the original tissues.
  • The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms.
  • Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / pathology. Subrenal Capsule Assay
  • [MeSH-minor] Animals. Female. Humans. Immunophenotyping. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589579.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Gonzalez Bosquet E: [Elevated Ca 19.9 tumor marker without evidence of malignancy]. Medicina (B Aires); 2007;67(3):285-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elevated Ca 19.9 tumor marker without evidence of malignancy].
  • Tumor markers are a useful tool for surveillance of oncologic patients, whereas their role in the diagnosis of a malignancy is controversial.
  • We present the case of a woman with a benign ovarian cyst with an unexpected elevation of Ca 19.9 after laparoscopic bilateral anexectomy.
  • [MeSH-major] CA-19-9 Antigen / blood. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Cysts / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628919.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


82. Zhang WY, Pan Y, Zhu LR, Zhang JZ, Zhang M, Feng K, Zhou L, Yu L, Zhang XM, Ng SW: [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]. Zhonghua Yi Xue Za Zhi; 2005 Nov 9;85(42):2988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
  • OBJECTIVE: To investigate the expression status of topoisomerase IIIa in epithelial ovarian tumor and the relationship between the expression status of topoisomerase IIIa and pathological type and clinical stage of epithelial ovarian carcinoma.
  • METHODS: Immunohistochemistry was carried out in the samples of ovarian tumor obtained during operation from 169 patients, aged 28 approximately 59, 18 cases with serous cystadenoma, 30 cases with serous borderline cystadenoma, 37 serous cystadenocarcinoma, 10 cases with mucous cystadenoma, 20 mucous borderline cystadenoma, 26 mucous cystadenocarcinoma, 19 cases with endometrial carcinoma of ovary, and 9 cases with clear cell carcinoma.
  • RESULTS: The expression rate of topoisomerase IIIa was 17.9% in the benign ovarian tumors, 74.0% in the borderline cystadenoma, and 42.7% in the malignant tumors with statistical significance among them (chi(2) = 24.657, P < 0.001).
  • CONCLUSION: Topoisomerase IIIa is highly expressed in epithelial ovarian carcinoma, and its expression level is correlated with the character and type of tumor tissues.
  • [MeSH-major] DNA Topoisomerases, Type I / biosynthesis. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Cystadenoma, Mucinous / enzymology. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / enzymology. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324386.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.2 / DNA topoisomerase III
  •  go-up   go-down


83. Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GM, Kolkman-Uljee SM, van Eijk R, Cornelisse CJ, Fleuren GJ, van Engeland M: Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol; 2005 Oct 10;23(29):7257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors.
  • PURPOSE: Ovarian serous borderline tumors (SBT) are characterized by arborizing papillae lined by stratified epithelial cells, varying atypia, and absence of stromal invasion.
  • Originally, these tumors have been classified as borderline because they behaved in a remarkably indolent manner, even with widespread tumor deposits called implants and the presence of lymph node involvement.
  • The purpose of this study was to further unravel the genetic pathways through which SBTs develop, with a special focus on explaining the generally benign SBT behavior.
  • MATERIALS AND METHODS: We generated RNA expression profiles of 38 ovarian serous neoplasms.
  • CONCLUSION: We propose that the putative tumor suppressor genes Dusp 4 and Serpina 5 provide a major clue to the indolent behavior of SBTs.
  • [MeSH-major] Neoplasms, Cystic, Mucinous, and Serous / genetics. Ovarian Neoplasms / genetics. Protein C Inhibitor / genetics. Protein Tyrosine Phosphatases / genetics
  • [MeSH-minor] Dual-Specificity Phosphatases. Female. Gene Expression. Gene Expression Profiling. Genes, Tumor Suppressor. Genes, ras / genetics. Humans. Matrix Metalloproteinase 9 / genetics. Mitogen-Activated Protein Kinase Phosphatases. Mutation. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16087957.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein C Inhibitor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP4 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


84. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG: Pediatric borderline ovarian tumors: a retrospective analysis. J Pediatr Surg; 2010 Oct;45(10):1955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric borderline ovarian tumors: a retrospective analysis.
  • BACKGROUND/PURPOSE: Borderline ovarian tumors (BOTs) are uncommon in the pediatric population, and there have been limited studies that have included a small number of patients.
  • RESULTS: Twenty-nine patients (median age, 18 years) had a large-sized tumor (median, 19.8 cm).
  • The permanent section histology revealed 25 mucinous (86.2%) and 4 serous type tumors (13.8%).
  • In 2 cases, the suspected recurrences were found to be other benign ovarian tumors.
  • In one case that was initially treated with left ovarian cystectomy for a mucinous BOT, subsequent left salpingo-oophorectomy confirmed recurrence of a mucinous BOT at 16-month follow-up.
  • The last case was a newly developed primary ovarian mucinous carcinoma with no evidence of recurrence of a previous mucinous BOT at 26-month follow-up.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Female. Humans. Infertility, Female / prevention & control. Ovariectomy / adverse effects. Ovariectomy / methods. Ovary / pathology. Ovary / surgery. Retrospective Studies. Salpingectomy / methods. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20920712.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Yoshida A, Sarian LO, Andrade LA, Pignataro F, Pinto GA, Derchain SF: Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int J Gynecol Cancer; 2007 May-Jun;17(3):607-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
  • The objective of this study was to assess the expression of Cyclooxygenase-2 (COX-2) and cell proliferation activity (Ki67 expression) in benign, borderline, and malignant serous and mucinous ovarian tumors.
  • Expression of COX-2 and Ki67 proteins were evaluated by immunohistochemistry, in paraffin-embedded sections of ovarian epithelial tumors.
  • The study included 113 serous (67 benign, 15 borderline, and 31 malignant) and 85 mucinous (48 benign, 28 borderline, and 9 malignant) tumors, removed from women who underwent laparotomy between January 1997 and December 2003.
  • From benign to malignant tumors, there was a progressive positive trend in COX-2 expression in both serous and mucinous tumors, more evident in mucinous ones (P < 0.001).
  • Comparing histologic types, COX-2 expression was more prominent in serous than in mucinous benign tumors (P < 0.01), but this difference was not significant in the borderline (P= 0.11) or malignant categories (P= 0.71).
  • There was a progressive Ki67 positivity in line with the tumor histologic gradient for both serous (P < 0.01) and mucinous lesions (P < 0.01), but this increasing expression did not correlate with COX-2 expression in the present series (P= 0.78).
  • There was a higher COX-2 expression in serous ovarian adenomas than in mucinous ones.
  • COX-2 positivity increases in line with the morphologic gradient, from benign to malignant in both histologic types, but it was more prominent in mucinous lesions, pointing to different oncogenic pathways related to different histologic types.
  • A correlation between the expression of COX-2 and Ki67 was not found, suggesting that COX-2 may be required for carcinogenesis, but this pathway is not responsible for cell proliferation in ovarian tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cell Proliferation. Cyclooxygenase 2 / metabolism. Cystadenocarcinoma, Serous / metabolism. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Humans. Ki-67 Antigen / metabolism. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504375.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


86. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res; 2006 Jan 15;12(2):432-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
  • PURPOSE: The objective was to identify and characterize low molecular weight proteins/peptides in urine and their posttranslational modifications that might be used as a screening tool for ovarian cancer.
  • EXPERIMENTAL DESIGN: Urine samples collected preoperatively from postmenopausal women with ovarian cancer and benign conditions and from nonsurgical controls were analyzed by surface-enhanced laser desorption/ionization mass spectrometry and two-dimensional gel electrophoresis.
  • Quantitative and semiquantitative ELISAs were developed for preliminary validation in patients of 128 ovarian cancer, 52 benign conditions, 44 other cancers, and 188 healthy controls.
  • RESULTS: A protein (m/z approximately 17,400) with higher peak intensities in cancer patients than in benign conditions and controls was identified and subsequently defined as eosinophil-derived neurotoxin (EDN).
  • A glycosylated form of EDN was specifically elevated in ovarian cancer patients.
  • Modified forms EDN and osteopontin fragments were elevated in early-stage ovarian cancers and a combination of both resulted to 93% specificity and 72% sensitivity.
  • CONCLUSIONS: Specific elevated posttranslationally modified urinary EDN and osteopontin COOH-terminal fragments in ovarian cancer might lead to potential noninvasive screening tests for early diagnosis.
  • [MeSH-major] Biomarkers, Tumor / urine. Eosinophil-Derived Neurotoxin / urine. Neoplasms, Glandular and Epithelial / urine. Ovarian Neoplasms / urine. Sialoglycoproteins / urine
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Clear Cell / urine. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / urine. Amino Acid Sequence. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Carcinoma, Endometrioid / urine. Case-Control Studies. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystadenocarcinoma, Serous / urine. Electrophoresis, Gel, Two-Dimensional. Enzyme-Linked Immunosorbent Assay. Female. Glycosylation. Humans. Molecular Sequence Data. Neoplasm Invasiveness. Osteopontin. Prognosis. Proteome. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jan 15;12(2):323-7 [16428467.001]
  • (PMID = 16428483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA 105009; United States / NCI NIH HHS / CA / R21 CA 111949-01; United States / NCI NIH HHS / CA / U01 CA 86381
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin; EC 3.1.- / Eosinophil-Derived Neurotoxin
  •  go-up   go-down


87. Hascalik S, Celik O, Sarac K, Meydanli MM, Alkan A, Mizrak B: Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. Gynecol Obstet Invest; 2005;60(3):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Spectroscopy analysis of serous, mucinous and undifferentiated carcinoma of the ovary revealed Cho, lactate and lipid signals, but granulosa-theca cell tumor showed only a lipid signal.
  • The Cho signal was obtained from only 3 patients with mature cystic teratoma but none of the other benign ovarian tumors and pelvic abscesses.
  • A lipid signal was detected in 3 patients diagnosed with pelvic abscess and all benign ovarian tumors.
  • CONCLUSION: MRS demonstrates significant differences in metabolite concentration between benign and malignant ovarian tumors and pelvic abscesses.
  • [MeSH-minor] Abdominal Abscess / metabolism. Abdominal Abscess / pathology. Adult. Aged. Choline / metabolism. Creatine / metabolism. Dermoid Cyst / metabolism. Dermoid Cyst / pathology. Diagnosis, Differential. Endometriosis / metabolism. Endometriosis / pathology. Female. Granular Cell Tumor / metabolism. Granular Cell Tumor / pathology. Humans. Lipid Metabolism. Middle Aged. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Neoplasms, Cystic, Mucinous, and Serous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Protons. Teratoma / metabolism. Teratoma / pathology

  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15920339.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


88. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ: Intraoperative assessment of ovarian tumors: a 5-year review with assessment of discrepant diagnostic cases. Int J Gynecol Pathol; 2006 Jul;25(3):216-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative assessment of ovarian tumors: a 5-year review with assessment of discrepant diagnostic cases.
  • Frozen section is often requested in the intraoperative assessment of patients, presenting with ovarian masses, to provide guidance for appropriate surgical management.
  • To assess the accuracy of frozen section and identify causes of diagnostic error, we reviewed 914 consecutive ovarian frozen sections performed over a 5-year period in 2 laboratories; one of which provides a general surgical pathology service and, the other, a specialist gynecologic pathology service.
  • The series included 552 benign lesions (60.4%), 96 borderline (atypical proliferating) epithelial tumors (10.5%), and 266 malignancies (29.1%).
  • Underdiagnosis of tumor type accounted for 32 of 43 discrepant cases and was most frequent in borderline mucinous tumors.
  • The most common cause of overdiagnosis was the misinterpretation of serous cystadenofibroma as borderline serous tumor.
  • This study confirms that ovarian frozen section is a generally reliable technique, but there are problematic areas, particularly involving the assessment of borderline tumors.
  • [MeSH-major] Diagnostic Errors / statistics & numerical data. Intraoperative Care / methods. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / pathology. Diagnosis, Differential. Female. Frozen Sections. Humans. Pathology, Surgical / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810056.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP: Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res; 2007 Aug 01;13(15 Pt 1):4422-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
  • PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging.
  • However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases.
  • The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125.
  • CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability.
  • RESULTS: hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125.
  • CONCLUSION: We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Serine Endopeptidases / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / diagnosis. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Prognosis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671125.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083636; United States / NCI NIH HHS / CA / P50 CA83636; United States / NCI NIH HHS / CA / R21CA093568
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / trypsin-like serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


90. Inai K, Shimizu Y, Kawai K, Tokunaga M, Soda M, Mabuchi K, Land CE, Tokuoka S: A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report. J Radiat Res; 2006 Mar;47(1):49-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report.
  • The present article describes the series of incident primary ovarian tumors in the Life Span Study (LSS) cohort of the Radiation Effects Research Foundation, with particular emphasis on case ascertainment and characterization of histological features of the tumors.
  • We identified 723 ovarian tumors (260 malignant, 463 benign) in 648 individuals of about 70,000 female LSS subjects; 71 cases had more than one ovarian tumor.
  • We histologically confirmed 601 tumors (182 malignant, 419 benign tumors).
  • The most frequent histological type was common epithelial tumor (90.7% for malignant and 59.7% for benign tumors).
  • The distributions of ovarian tumors by histological type were similar to those from other studies.
  • Among malignancies, the frequency of common epithelial types relative to other tumor types increased with radiation dose (p = 0.02).
  • Among benign tumors, the relative frequency of sex-cord stromal tumors increased with radiation dose (p = 0.04).
  • The women with mucinous cancer had better survival than those with serous cancers (p = 0.03).
  • Within tumor types, there was no consistent pattern of survival by radiation dose.
  • Variations in histological types of ovarian tumors in response to radiation dose, suggested by the case series data need to be followed up by population-based incidence analysis.
  • [MeSH-major] Neoplasms, Radiation-Induced / mortality. Neoplasms, Radiation-Induced / pathology. Nuclear Warfare / statistics & numerical data. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Risk Assessment / methods. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571918.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31012; United States / NCI NIH HHS / CP / N01-CP-71015
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  •  go-up   go-down


91. Kitagawa H, Okabayashi T, Nishimori I, Kobayashi M, Sugimoto T, Akimori T, Kohsaki T, Miyaji E, Onishi S, Araki K: Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy. Int J Gastrointest Cancer; 2006;37(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy.
  • At 8 mo postpartum, she became aware of an upper abdominal tumor.
  • The patient underwent tumor resection at 11 mo postpartum.
  • Pathological examination of the tumor revealed mucin-producing columnar epithelial cells lining the cystic wall with ovarian-type stromal tissue and no findings indicative of malignancy, giving a diagnosis of mucinous cystic adenoma of the pancreas.
  • Postpartum rapid growth of a benign mucinous cystic neoplasm might be linked to the production of female sex hormones during lactation.
  • [MeSH-major] Adenoma / pathology. Cystadenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] World J Surg Oncol. 2005 Sep 07;3:59 [16146567.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):282-7 [15780564.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):203-5 [15221374.001]
  • (PMID = 17290080.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Güney M, Oral B, Demir F, Ozsoy M, Kapucuoğlu N: Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report. Eur J Gynaecol Oncol; 2006;27(3):304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report.
  • Benign cystic teratoma of the ovary (BCTO) is the most common ovarian germ cell tumor occurring predominantly in early adulthood.
  • Most benign cystic teratomas with malignant transformations are squamous cell carcinomas with just 6.8% being adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800267.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


93. Kushida Y, Haba R, Kadota K, Doi T, Ishikawa M, Hirakawa E, Kira M: Composite mucinous and granulosa cell tumor of the ovary. Pathol Int; 2005 Dec;55(12):797-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite mucinous and granulosa cell tumor of the ovary.
  • A composite mucinous and granulosa cell tumor of the ovary in a 76-year-old woman is herein reported.
  • At laparotomy this tumor proved to be a solid and cystic mass measuring 10 cm in greatest diameter.
  • Many of the cysts were lined with a benign mucinous epithelium of the endocervical type, and solid areas contained a proliferation of granulosa cells.
  • A theca cell component was also present in areas adjacent to the mucinous epithelium.
  • The coexistence of mucinous and granulosa cell tumor is extremely rare and only four such cases have previously been reported in the literature, and the histogenesis of this tumor has not yet been elucidated.
  • In the present case it is suggested that the granulosa cell element commenced as a reactive stromal hyperplasia in the wall of the pre-existing mucinous neoplasm and thereafter progressed to the point of producing a tumor-like mass or neoplastic changes.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287496.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


94. Balci O, Gezginc K, Karatayli R, Acar A, Celik C, Colakoglu MC: Management and outcomes of adnexal masses during pregnancy: a 6-year experience. J Obstet Gynaecol Res; 2008 Aug;34(4):524-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postoperative pathology results of the patients were functional ovarian cysts in 14 cases (41.1%), endometrioma in eight cases (23.5%), dermoid cyst in six cases (17.6%), serous cystadenoma in two cases (5.8%), mucinous cystadenoma in one case (2.9%), para-ovarian cyst in one case (2.9%), and borderline serous tumor in two cases (5.8%).
  • Most masses at pregnancies were benign in character and our malignity rate was low.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Obstet Gynaecol Res. 2009 Jun;35(3):597-8 [19527409.001]
  • (PMID = 18946936.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A: High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
  • The molecular etiology of epithelial ovarian cancer remains unclear.
  • Using microarray expression analysis, we recently reported that expression of the insulin-like growth factor binding protein-2 (IGFBP-2) gene is elevated in advanced epithelial ovarian cancers.
  • The aim of this study was to further delineate the role of IGFBP-2 in the pathoetiology of epithelial ovarian cancer and determine if elevated ovarian cancer IGFBP-2 gene expression is reflected in serum.
  • Relative IGFBP-2 expression was measured using quantitative real-time polymerase chain reaction in 113 epithelial ovarian cancers and 6 normal ovarian surface epithelial samples.
  • Preoperative serum IGFBP-2 levels were measured by radioimmunoassay in 84 women (42 ovarian cancers, 26 benign gynecological conditions, and 10 healthy female controls).
  • Ovarian cancers demonstrated 38-fold higher mean IGFBP-2 expression than normal ovarian epithelium (P < 0.01).
  • Serum IGFBP-2 levels were elevated in women with early- and advanced-stage ovarian cancer compared to controls and patients with benign gynecological conditions (P = 0.05 and P < 0.01, respectively).
  • Epithelial ovarian cancers express high levels of IGFBP-2 relative to normal ovarian epithelium, and this is associated with elevated serum IGFBP-2 levels compared to both normal controls and patients with benign gynecological disease.
  • Our findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis.
  • Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Regulation, Neoplastic / genetics. Insulin-Like Growth Factor Binding Protein 2 / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. RNA, Messenger / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / surgery. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / genetics. Ovary / pathology. Precancerous Conditions / blood. Precancerous Conditions / genetics. Precancerous Conditions / surgery. Preoperative Care. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884361.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / RNA, Messenger
  •  go-up   go-down


96. Shi HR, Zhang RT: [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer]. Ai Zheng; 2009 Aug;28(8):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
  • This study was to investigate the expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer.
  • METHODS: The expression of P53, P21WAF1 and CDK1 proteins in 20 specimens of normal ovarian tissues, 20 specimens of benign epithelial ovarian tumor and 76 specimens of epithelial ovarian cancer was detected by immunohistochemistry.
  • Their correlations to the clinicopathologic characteristics of epithelial ovarian cancer and their interrelationships were analyzed.
  • RESULTS: Significant differences were noted in the positive rates of P53, P21WAF1 and CDK1 proteins between epithelial ovarian cancer and normal ovarian tissues, benign ovarian tumors (P < 0.05).
  • In epithelial ovarian cancer, up-regulation of P53 protein was associated with advanced FIGO stage and poor differentiation; down-regulation of P21WAF1 protein was associated with advanced FIGO stage; CDK1 showed no association with any clinicopathologic factors.
  • CONCLUSIONS: P53 protein is related to the malignancy of epithelial ovarian cancer, P53 and P21WAF1 protein may be related to the malignant development of epithelial ovarian cancer.
  • CDK1 detection may be helpful in the early diagnosis of epithelial ovarian cancer.
  • [MeSH-major] CDC2 Protein Kinase / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664338.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


97. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol; 2007 Jun;105(3):578-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of mammaglobin B in epithelial ovarian carcinomas.
  • OBJECTIVE: Mammaglobin B is a uteroglobin gene family member recently found highly differentially expressed in serous papillary ovarian cancer by gene expression profiling.
  • In order to evaluate its potential as a novel ovarian cancer biomarker, in this study we quantified and compared Mammaglobin B expression in various histologic types of epithelial ovarian carcinomas (EOC).
  • METHODS: Mammaglobin B expression was evaluated by real-time PCR and/or immunohistochemistry in fresh-frozen biopsies and paraffin-embedded tissues derived from a total of 137 patients including 69 primary EOC with different histologies, 28 serous papillary omental metastasis, 8 borderline tumors, 26 benign cystadenomas and 14 normal ovaries.
  • RESULTS: High levels of Mammaglobin B gene expression were detected in 100% (68 out of 68) of the ovarian cancer biopsies tested by real-time PCR.
  • In contrast, normal human ovarian surface epithelium (HOSE) expressed negligible levels of Mammaglobin B mRNA (EOC versus HOSE, p<0.01).
  • Although Mammaglobin B gene expression levels were higher in endometrioid, mucinous and undifferentiated tumors when compared to serous papillary tumors, clear cell tumors and those with mixed histology, these differences were not statistically significant.
  • In agreement with real-time PCR results, EOC were found to express significantly higher levels of Mammaglobin B protein when compared to normal ovaries and benign cystadenomas (p<0.01).
  • CONCLUSIONS: Mammaglobin B gene is highly expressed in EOC and may represent a novel molecular marker for multiple histological types of ovarian cancer.
  • Additional studies to evaluate the clinical utility of Mammaglobin B as a diagnostic and/or therapeutic target in ovarian cancer are warranted.
  • [MeSH-major] Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / immunology. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Mammaglobin B. Middle Aged. Myelin Proteins. Polymerase Chain Reaction. Proteolipids. Secretoglobins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


98. Simaga S, Osmak M, Babic D, Sprem M, Vukelic B, Abramic M: Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade. Int J Gynecol Cancer; 2005 May-Jun;15(3):438-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade.
  • In an attempt to identify glycolytic capacity of normal and neoplastic human ovary, total lactate dehydrogenase (LDH) activity was measured in tissue cytosol originating from 69 patients (18 with benign ovarian tumor, 34 with ovarian carcinoma, six with nonepithelial ovarian malignant tumors, and 11 with tumor metastatic to ovary) and compared to the LDH activity of normal ovarian tissues (n = 19).
  • Median value of total LDH-specific activity expressed as U/mg protein was 0.546 in normal tissues, 0.584 in benign tumors, 1.071 in malignancies metastatic to ovaries, 0.872 in nonepithelial primary ovarian tumors, and 0.818 in primary carcinomas.
  • A significant rise in LDH-specific activity was found in malignant primary and secondary tumors of epithelial and nonepithelial origin, but not in benign neoplasms, compared to the activity in normal tissue.
  • Ovarian carcinomas of serous histologic type did not differ in LDH activity from mucinous tumors.
  • The subgroup of grade 1 tumors did not differ in LDH activity from normal and benign ovarian tissue.
  • Obtained results suggest that direct correlation might exist between ovarian epithelial tumor grade and lactate dehydrogenase activity.
  • [MeSH-major] L-Lactate Dehydrogenase / analysis. L-Lactate Dehydrogenase / metabolism. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / pathology. Ovary / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882167.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


99. Ueda M, Toji E, Noda S: Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):794-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
  • It has been shown that ovarian low-grade serous carcinoma evolves out of a stepwise progression from benign serous cystadenoma to serous borderline tumor (SBT) to micropapillary serous carcinoma (MPSC), and that BRAF activation is a very early somatic event in the tumorigenesis.
  • We postulated that BRAF could be a SBT susceptibility gene, and investigated both germ line and somatic mutations of BRAF V599E in 104 ovarian cancer patients.
  • BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33%) of 3 MPSCs, 1 (17%) of 6 endometrioid carcinomas, but not detected in 42 conventional serous carcinomas, 12 mucinous borderline tumors, 10 mucinous, and 10 clear-cell carcinomas.
  • We also found no BRAF V599E mutation in 101 normal healthy women and 10 well-established ovarian cancer cell lines.
  • [MeSH-major] Cystadenoma, Serous / genetics. Mutation. Ovarian Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309670.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


100. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors






Advertisement